<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//www.merck.com/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-is-the-first-anti-pd-1-therapy-approved-in-china-for-advanced-melanoma/</loc>
		<lastmod>2025-03-08T04:35:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2018-financial-results/</loc>
		<lastmod>2025-03-08T04:35:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-hepatocellular-carcinoma/</loc>
		<lastmod>2025-03-08T04:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-reinforces-commitment-to-responsible-pricing/</loc>
		<lastmod>2025-03-08T04:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-investigational-hiv-therapy-doravirine/</loc>
		<lastmod>2025-03-08T04:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2018-dividend/</loc>
		<lastmod>2025-03-08T04:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-monotherapy-met-a-primary-endpoint-in-the-phase-3-keynote-048-trial-significantly-improving-os-as-first-line-therapy-in-head-and-neck-squamous-cell-carcinoma-patients-w/</loc>
		<lastmod>2025-03-08T04:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-japan-for-brca-mutated-metastatic-breast-cancer/</loc>
		<lastmod>2025-03-08T04:35:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-studies-of-investigational-hiv-therapy-doravirine-including-pivotal-drive-forward-trial-at-aids-2018/</loc>
		<lastmod>2025-03-08T04:35:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-metastatic-squa/</loc>
		<lastmod>2025-03-08T04:35:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-significantly-delays-disease-progression-in-phase-3-first-line-solo-1-trial-for-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2018-sales-and-earnings-conference-call-on-july-27/</loc>
		<lastmod>2025-03-08T04:35:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-findings-from-who-led-study-of-investigational-heat-stable-carbetocin-for-preventing-excessive-bleeding-after-childbirth/</loc>
		<lastmod>2025-03-08T04:35:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/late-breaking-data-to-be-presented-from-the-comparative-trials-with-sitagliptin-composit-program-on-the-continuation-of-januvia-sitagliptin-treatment-among-patients-initiating-insulin-therap/</loc>
		<lastmod>2025-03-08T04:35:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-new-data-from-the-comparative-trials-with-sitagliptin-composit-clinical-trial-program-with-januvia-sitagliptin/</loc>
		<lastmod>2025-03-08T04:35:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-supplemental-biologics-license-application-for-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-in-advanced-melanoma/</loc>
		<lastmod>2025-03-08T04:35:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumors-express-pd-l1-cps-greater-than-or-equal-to-1/</loc>
		<lastmod>2025-03-08T04:35:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-gardasil9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and/</loc>
		<lastmod>2025-03-08T04:35:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-treatment-of-refractory-or-relapsed-primary-mediastinal-large-b-cell-lymphoma-pmbcl/</loc>
		<lastmod>2025-03-08T04:35:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-showed-promising-anti-tumor-activity-in-patients-with-advanced-small-cell-lung-cancer-sclc-in-phase-2-keynote-158-study/</loc>
		<lastmod>2025-03-08T04:35:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:35:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/eisai-and-merck-announce-data-at-2018-asco-annual-meeting-from-investigational-studies-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-therapy-in-four-different-tumor-type/</loc>
		<lastmod>2025-03-08T04:35:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-long-term-survival-benefit-based-on-four-and-five-years-of-follow-up-from-two-pivotal-studies-in-advanced-melanoma/</loc>
		<lastmod>2025-03-08T04:35:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-in-first-line-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-in-phase-3-keynote-40/</loc>
		<lastmod>2025-03-08T04:35:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-showed-overall-response-rate-of-nearly-40-percent-as-first-line-therapy-in-patients-with-advanced-clear-cell-renal-cell-carcinoma-rcc-in-phase-2-keynot/</loc>
		<lastmod>2025-03-08T04:35:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-premier-inc-collaborating-to-help-reduce-clostridium-difficile-c-diff-infection/</loc>
		<lastmod>2025-03-08T04:35:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-monotherapy-significantly-improved-overall-survival-in-keynote-042-study-as-first-line-treatment-for-locally-advanced-or-metastatic-nsclc-patients-whose-tumors-expressed/</loc>
		<lastmod>2025-03-08T04:35:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-and-progression-free-survival-as-first-line-treatment-for-squamous-non-small-cell-lung-cancer-nsclc-in-pivotal/</loc>
		<lastmod>2025-03-08T04:35:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/eisai-and-merck-provide-update-on-supplemental-new-drug-application-snda-for-lenvatinib-in-first-line-unresectable-hepatocellular-carcinoma/</loc>
		<lastmod>2025-03-08T04:35:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-makes-shipments-of-investigational-ebola-zaire-vaccine-v920-rvsv%e2%88%86g-zebov-gp-to-world-health-organization/</loc>
		<lastmod>2025-03-08T04:35:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-data-from-mercks-leading-immuno-oncology-clinical-development-program-in-over-25-tumor-types-to-be-presented-at-2018-asco-annual-meeting/</loc>
		<lastmod>2025-03-08T04:35:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2018-dividend/</loc>
		<lastmod>2025-03-08T04:35:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2018-financial-results/</loc>
		<lastmod>2025-03-08T04:35:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-keynote-407-trial/</loc>
		<lastmod>2025-03-08T04:35:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-expand-mrna-cancer-vaccines-collaboration/</loc>
		<lastmod>2025-03-08T04:35:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-sbla-for-keytruda-pembrolizumab-in-combination-with-pemetrexed-alimta-and-platinum-chemotherapy-based-on-results-from-phase-3-keynote/</loc>
		<lastmod>2025-03-08T04:35:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-disease-recurrence-or-death-by-more-than-40-percent-compared-to-placebo-as-adjuvant-therapy-in-resected-high-risk-stage-iii-melanoma/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-phase-three-studies-for-pcv-15-v114-its-investigational-pneumococcal-disease-vaccine/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-advances-clean-energy-goals-with-invenergy/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pivotal-phase-3-study-of-mercks-investigational-beta-lactamase-inhibitor-relebactam-in-combination-with-imipenem-cilastatin-demonstrated-favorable-overall-response-against-certain-imipenem/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-medicines-agency-validates-type-ii-variation-for-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-alimta-and-platinum-chemotherapy-as-first-line-therapy-i/</loc>
		<lastmod>2025-03-08T04:35:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-2018-energy-star-sustained-excellence-award/</loc>
		<lastmod>2025-03-08T04:35:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-olaparib-in-brca-mutated-her2-negative-metastatic-breast-cancer/</loc>
		<lastmod>2025-03-08T04:35:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/incyte-and-merck-provide-update-on-phase-3-study-of-epacadostat-in-combination-with-keytruda-pembrolizumab-in-patients-with-unresectable-or-metastatic-melanoma/</loc>
		<lastmod>2025-03-08T04:35:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-monotherapy-met-primary-endpoint-in-phase-3-keynote-042-study-significantly-improving-os-as-first-line-therapy-in-locally-advanced-or-metastatic-nsclc-patients-expressi/</loc>
		<lastmod>2025-03-08T04:35:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-jennifer-zachary-as-general-counsel/</loc>
		<lastmod>2025-03-08T04:35:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc/</loc>
		<lastmod>2025-03-08T04:35:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2018-sales-and-earnings-conference-call-on-may-1/</loc>
		<lastmod>2025-03-08T04:35:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/eisai-co-ltd-and-merck-enter-global-strategic-oncology-collaboration-for-lenvima-lenvatinib-mesylate/</loc>
		<lastmod>2025-03-08T04:35:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-for-treatment-of-advanced-cervical-cancer/</loc>
		<lastmod>2025-03-08T04:35:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting/</loc>
		<lastmod>2025-03-08T04:35:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018/</loc>
		<lastmod>2025-03-08T04:35:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/first-of-its-kind-study-reveals-concern-about-the-future-of-the-veterinary-profession/</loc>
		<lastmod>2025-03-08T04:35:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-mk-8931-for-the-treatment-of-people-with-prodromal-alzheimers-disease/</loc>
		<lastmod>2025-03-08T04:35:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/selumetinib-granted-orphan-drug-designation-by-the-u-s-fda-for-neurofibromatosis-type-1/</loc>
		<lastmod>2025-03-08T04:35:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-viralytics-announce-acquisition-agreement-expanding-mercks-leading-immuno-oncology-pipeline/</loc>
		<lastmod>2025-03-08T04:35:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ferring-pharmaceuticals-and-merck-announce-completion-of-largest-clinical-trial-ever-conducted-in-postpartum-hemorrhage/</loc>
		<lastmod>2025-03-08T04:35:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pro-football-hall-of-famer-and-cancer-survivor-jim-kelly-joins-merck-to-challenge-america-to-raise-funds-for-the-cancer-community/</loc>
		<lastmod>2025-03-08T04:35:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2017-financial-results/</loc>
		<lastmod>2025-03-08T04:35:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytrudar-pembrolizumab-significantly-improved-overall-survival-and-progression-free-survival-as-first-line-treatment-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-p/</loc>
		<lastmod>2025-03-08T04:35:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/first-time-data-for-mercks-keytruda-pembrolizumab-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma-hcc-to-be-presented-at-2018-asco-gi-symposium/</loc>
		<lastmod>2025-03-08T04:35:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2018-dividend/</loc>
		<lastmod>2025-03-08T04:35:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/inge-thulin-elected-to-merck-board-of-directors/</loc>
		<lastmod>2025-03-08T04:35:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-at-the-36th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-recurrence-free-survival-compared-to-placebo-as-adjuvant-therapy-in-patients-with-stage-3-resected-high-risk-melanoma-eortc1325-k/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/eisai-and-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumab-as-combination-therapy-for-advanced-and-or-metastatic-rena/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-approves-lynparza-olaparib-in-germline-brca-mutated-metastatic-breast-cancer/</loc>
		<lastmod>2025-03-08T04:35:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-use-in-the-treatment-of-patients-with-urothelial-carcinoma-that-is-unresectable-with-radical-surgery-who-have-progressed-following/</loc>
		<lastmod>2025-03-08T04:35:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fda-approval-for-ervebo-ebola-zaire-vaccine-live/</loc>
		<lastmod>2025-03-08T04:35:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-by-fda-as-first-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer/</loc>
		<lastmod>2025-03-08T04:35:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-oncologic-drugs-advisory-committee-odac-recommends-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-high-risk-non-muscle-invasive-bladder-cancer-nmibc/</loc>
		<lastmod>2025-03-08T04:35:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/</loc>
		<lastmod>2025-03-08T04:35:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-begins-tender-offer-to-acquire-arqule/</loc>
		<lastmod>2025-03-08T04:35:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-vaki-to-further-broaden-its-leadership-position-in-aquaculture-to-advance-fish-health-and-welfare/</loc>
		<lastmod>2025-03-08T04:35:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-recommended-by-fda-advisory-committee-for-first-line-maintenance-therapy-in-germline-brca-mutated-metastatic-pancreatic-cancer-that-has-not-progressed-on-platinum-based-chemo/</loc>
		<lastmod>2025-03-08T04:35:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/data-from-exploratory-analysis-show-mercks-keytruda-pembrolizumab-improved-overall-survival-as-monotherapy-for-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-regard/</loc>
		<lastmod>2025-03-08T04:35:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-infections-due-to-aerobic-gram-negative-organisms-in-adults-with-limited-tre/</loc>
		<lastmod>2025-03-08T04:35:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-china-as-a-first-line-maintenance-therapy-in-brca-mutated-brcam-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-arqule-advancing-leadership-in-oncology/</loc>
		<lastmod>2025-03-08T04:35:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-certain-patients-with-high-risk-non-muscle-invasive-bladder-cance/</loc>
		<lastmod>2025-03-08T04:35:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-evercore-isi-healthconx-conference-2019/</loc>
		<lastmod>2025-03-08T04:35:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-now-approved-in-china-for-first-line-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-nsclc-in-combination-with-chemotherapy/</loc>
		<lastmod>2025-03-08T04:35:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-two-new-regimens-of-mercks-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:35:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/bravecto-plus-fluralaner-and-moxidectin-topical-solution-for-cats-receives-approval-from-us-food-and-drug-administration/</loc>
		<lastmod>2025-03-08T04:35:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-bayers-investigational-drug-vericiguat-meets-primary-endpoint-in-phase-3-study-of-patients-with-worsening-chronic-heart-failure/</loc>
		<lastmod>2025-03-08T04:35:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2020-dividend/</loc>
		<lastmod>2025-03-08T04:35:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-ervebo-ebola-zaire-vaccine-rvsv%ce%b4g-zebov-gp-live-granted-conditional-approval-in-the-european-union/</loc>
		<lastmod>2025-03-08T04:35:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/us-fda-accepts-regulatory-submission-of-new-drug-application-for-selumetinib-in-neurofibromatosis-type-1-nf1-and-grants-priority-review/</loc>
		<lastmod>2025-03-08T04:35:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2019-financial-results/</loc>
		<lastmod>2025-03-08T04:35:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-its-hiv-portfolio-at-the-17th-european-aids-conference/</loc>
		<lastmod>2025-03-08T04:35:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:35:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-eu-chmp-positive-opinion-for-investigational-v920-ebola-zaire-vaccine-for-protection-against-ebola-virus-disease/</loc>
		<lastmod>2025-03-08T04:35:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-issues-2018-2019-corporate-responsibility-report/</loc>
		<lastmod>2025-03-08T04:35:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-issues-2018-2019-corporate-responsibility-report/</loc>
		<lastmod>2025-03-08T04:35:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-third-quarter-2019-sales-and-earnings-conference-call-on-october-29/</loc>
		<lastmod>2025-03-08T04:35:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-two-applications-for-mercks-dificid-fidaxomicin-to-treat-children-aged-six-months-up-to-18-years-with-clostridium-difficile-infections/</loc>
		<lastmod>2025-03-08T04:35:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:35:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-more-than-doubled-median-radiographic-progression-free-survival-rpfs-in-brca1-2-or-atm-metastatic-castration-resistant-prostate-cancer-vs-standard-of-care-7-4-vs-3-6-mon/</loc>
		<lastmod>2025-03-08T04:35:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significant-increase-in-pathological-complete-response-versus-chemotherapy-as-neoadjuvant-therapy-in-early-stage-t/</loc>
		<lastmod>2025-03-08T04:35:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pivotal-restore-imi-2-phase-3-study-of-mercks-recarbrio-imipenem-cilastatin-and-relebactam-in-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp-met-prim/</loc>
		<lastmod>2025-03-08T04:35:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-phase-3-paola-1-trial-significantly-increased-progression-free-survival-as-first-line-maintenance-treatment-with-bevacizumab-for-newly-diagnosed-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/final-study-results-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment-in-advanced-endometrial-cancer-presented-at-esmo-2019-congress/</loc>
		<lastmod>2025-03-08T04:35:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment-for-patients-with-certain-types-of-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:35:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-pifeltro-doravirine-and-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-receive-us-fda-approval-for-use-in-appropriate-adults-living-with-hiv-1-who/</loc>
		<lastmod>2025-03-08T04:35:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pooled-analysis-continues-to-show-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-patien/</loc>
		<lastmod>2025-03-08T04:35:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-nine-safer-childbirth-cities-committed-to-reducing-maternal-deaths-and-narrowing-disparities-in-the-us/</loc>
		<lastmod>2025-03-08T04:35:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-mercks-biologics-license-application-bla-and-grants-priority-review-for-v920-the-companys-investigational-vaccine-for-ebola-zaire-virus/</loc>
		<lastmod>2025-03-08T04:35:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:35:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pivotal-new-data-from-mercks-broad-oncology-portfolio-at-esmo-2019-congress/</loc>
		<lastmod>2025-03-08T04:35:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:35:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-foundation-launches-five-year-initiative-to-reduce-disparities-in-hiv-care-for-vulnerable-and-underserved-southeastern-us-communities/</loc>
		<lastmod>2025-03-08T04:35:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-phase-3-paola-1-trial-met-primary-endpoint-as-first-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:35:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-highlights-new-data-from-leading-lung-cancer-clinical-development-program-at-the-iaslc-2019-world-conference-on-lung-cancer/</loc>
		<lastmod>2025-03-08T04:35:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-phase-3-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint/</loc>
		<lastmod>2025-03-08T04:35:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-leadership-changes-to-investor-relations-team/</loc>
		<lastmod>2025-03-08T04:35:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-new-monotherapy-indication-for-mercks-keytruda-pembrolizumab/</loc>
		<lastmod>2025-03-08T04:35:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-zerbaxa-3g-dose-ceftolozane-and-tazobactam-for-the-treatment-of-adults-with-hospital-acquired-pneumonia-hap-including-ventilator-associated-pneum/</loc>
		<lastmod>2025-03-08T04:35:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2019-financial-results/</loc>
		<lastmod>2025-03-08T04:35:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-medicines-agency-adopts-positive-opinion-for-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-advanced-renal-cell-carcino/</loc>
		<lastmod>2025-03-08T04:35:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-pathological-complete-response-pcr-in-pivotal-phase-3-keynote-522-trial-in-patients-with-tripl/</loc>
		<lastmod>2025-03-08T04:35:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-early-evidence-on-extended-delivery-of-investigational-anti-hiv-1-agent-islatravir-mk-8591-via-subdermal-implant/</loc>
		<lastmod>2025-03-08T04:35:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2019-dividend/</loc>
		<lastmod>2025-03-08T04:35:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-presentation-of-phase-2b-results-for-investigational-hiv-1-therapy-islatravir-mk-8591-at-ias-2019/</loc>
		<lastmod>2025-03-08T04:35:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/sure-petcare-launches-surefeed-microchip-pet-feeder-connect/</loc>
		<lastmod>2025-03-08T04:35:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-receive-third-breakthrough-therapy-designation-from-fda-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment/</loc>
		<lastmod>2025-03-08T04:35:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-highlights-commitment-to-hiv-research-with-presentations-for-investigational-anti-hiv-agent-mk-8591-at-ias-2019/</loc>
		<lastmod>2025-03-08T04:35:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-complicated-urinary-tract-and-complicated-intra-abdominal-bacterial-infections-w/</loc>
		<lastmod>2025-03-08T04:35:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2019-sales-and-earnings-conference-call-on-july-30/</loc>
		<lastmod>2025-03-08T04:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-mercks-supplemental-biologics-license-applications-for-keytruda-pembrolizumab-six-week-dosing-schedule-for-melanoma-and-multiple-other-indications/</loc>
		<lastmod>2025-03-08T04:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/cdc-advisory-committee-on-immunization-practices-acip-votes-to-provisionally-recommend-shared-clinical-decision-making-for-vaccination-of-adults-ages-27-45-with-gardasil9-harmonization-o/</loc>
		<lastmod>2025-03-08T04:36:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/cdc-advisory-committee-on-immunization-practices-acip-unanimously-votes-to-provisionally-update-recommendations-for-hepatitis-a-vaccination/</loc>
		<lastmod>2025-03-08T04:36:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-hosts-2019-investor-day-outlining-business-momentum-strong-expected-growth-and-focus-on-innovative-research-and-development/</loc>
		<lastmod>2025-03-08T04:36:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-for-use-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-monotherapy-for-patients-with-metastatic-small-cell-lung-cancer-sclc-with-disease-progression-on-or-after-platinum-based-chemotherapy-a/</loc>
		<lastmod>2025-03-08T04:36:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-two-new-indications-for-mercks-keytruda-pembrolizumab/</loc>
		<lastmod>2025-03-08T04:36:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ibm-kpmg-merck-and-walmart-to-collaborate-as-part-of-fdas-program-to-evaluate-the-use-of-blockchain-to-protect-pharmaceutical-product-integrity/</loc>
		<lastmod>2025-03-08T04:36:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-zerbaxa-ceftolozane-and-tazobactam-3g-dose-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp/</loc>
		<lastmod>2025-03-08T04:36:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-tilos-therapeutics/</loc>
		<lastmod>2025-03-08T04:36:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati/</loc>
		<lastmod>2025-03-08T04:36:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat/</loc>
		<lastmod>2025-03-08T04:36:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/results-evaluating-mercks-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-to-be-presented-at-2019-a/</loc>
		<lastmod>2025-03-08T04:36:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/five-year-survival-data-for-mercks-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer-nsclc-from-first-keynote-trial-at-2019-asco-annual-meeting/</loc>
		<lastmod>2025-03-08T04:36:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2019-dividend/</loc>
		<lastmod>2025-03-08T04:36:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrates-improved-overall-survival-as-first-line-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-final-analysis-of-pivo/</loc>
		<lastmod>2025-03-08T04:36:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-119-study-of-keytruda-pembrolizumab-monotherapy-in-previously-treated-patients-with-metastatic-triple-negative-breast-cancer/</loc>
		<lastmod>2025-03-08T04:36:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-peloton-therapeutics-bolstering-oncology-pipeline/</loc>
		<lastmod>2025-03-08T04:36:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-foundation-announces-grant-to-american-cancer-society-to-improve-access-to-cancer-care-in-resource-limited-settings/</loc>
		<lastmod>2025-03-08T04:36:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-research-from-mercks-broad-oncology-clinical-development-program-to-be-presented-at-2019-asco-annual-meeting/</loc>
		<lastmod>2025-03-08T04:36:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-analyses-for-januvia-sitagliptin-and-steglatro-ertugliflozin-and-real-world-data-studies-at-the-79th-scientific-sessions-of-the-american-diabetes-association/</loc>
		<lastmod>2025-03-08T04:36:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants/</loc>
		<lastmod>2025-03-08T04:36:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/katie-couric-joins-merck-and-cancer-advocates-to-support-patients-and-caregivers-through-the-expansion-of-your-cancer-game-plan-ycgp/</loc>
		<lastmod>2025-03-08T04:36:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2019-financial-results/</loc>
		<lastmod>2025-03-08T04:36:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-belsomra-suvorexant-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-the-treatment-of-insomnia-in-people-with-mild-to-moderate-alzheimers-disease-dementia/</loc>
		<lastmod>2025-03-08T04:36:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-eu-chmp-opinion-for-first-line-maintenance-treatment-in-brca-mutated-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:36:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-viola-davis-to-debut-a-touch-of-sugar-during-tribeca-film-festival/</loc>
		<lastmod>2025-03-08T04:36:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-062-trial-evaluating-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-advanced-gast/</loc>
		<lastmod>2025-03-08T04:36:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-expanded-monotherapy-label-for-mercks-keytruda-pembrolizumab/</loc>
		<lastmod>2025-03-08T04:36:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/results-of-phase-3-trial-evaluating-mercks-zerbaxa-ceftolozane-and-tazobactam-versus-meropenem-for-treatment-of-adult-patients-with-ventilated-nosocomial-pneumonia-vnp-to-be-present/</loc>
		<lastmod>2025-03-08T04:36:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer/</loc>
		<lastmod>2025-03-08T04:36:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-antelliq-corporation-to-become-leader-in-emerging-digital-technology-for-livestock-and-companion-animals/</loc>
		<lastmod>2025-03-08T04:36:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2019-sales-and-earnings-conference-call-on-april-30/</loc>
		<lastmod>2025-03-08T04:36:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-tender-offer-to-acquire-immune-design/</loc>
		<lastmod>2025-03-08T04:36:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-for-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer-nsclc-in-combination-with-chemotherapy/</loc>
		<lastmod>2025-03-08T04:36:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/data-for-mercks-keytruda-pembrolizumab-across-different-types-of-advanced-lung-cancer-presented-at-aacr-annual-meeting-2019/</loc>
		<lastmod>2025-03-08T04:36:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-adults-with-metastatic-squamous-non-small-cell-lung-cancer-nsc/</loc>
		<lastmod>2025-03-08T04:36:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ngm-bio-announce-extension-of-broad-multi-year-strategic-collaboration-to-2022/</loc>
		<lastmod>2025-03-08T04:36:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/selumetinib-granted-u-s-breakthrough-therapy-designation-in-neurofibromatosis-type-1/</loc>
		<lastmod>2025-03-08T04:36:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-begins-tender-offer-to-acquire-immune-design/</loc>
		<lastmod>2025-03-08T04:36:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-prices-5-0-billion-debt-offering/</loc>
		<lastmod>2025-03-08T04:36:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer/</loc>
		<lastmod>2025-03-08T04:36:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-medicines-agency-adopts-positive-opinion-for-mercks-keytruda-pembrolizumab-for-six-week-dosing-schedule-across-all-current-monotherapy-indications/</loc>
		<lastmod>2025-03-08T04:36:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-data-from-mercks-expanding-hiv-clinical-development-program-to-be-presented-at-croi-2019/</loc>
		<lastmod>2025-03-08T04:36:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-reduced-the-risk-of-disease-progression-or-death-as-first-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer/</loc>
		<lastmod>2025-03-08T04:36:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-monotherapy-for-third-line-treatment-of-patients-with-advanced-small-cell-lu/</loc>
		<lastmod>2025-03-08T04:36:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-immune-design/</loc>
		<lastmod>2025-03-08T04:36:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-the-adjuvant-treatment-of-patients-with-melanoma-with-involvement-of-lymph-nodes-following-complete-resection/</loc>
		<lastmod>2025-03-08T04:36:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-keynote-240-a-phase-3-study-of-keytruda-pembrolizumab-in-previously-treated-patients-with-advanced-hepatocellular-carcinoma/</loc>
		<lastmod>2025-03-08T04:36:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-adva/</loc>
		<lastmod>2025-03-08T04:36:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-reduced-risk-of-death-by-nearly-half-compared-to-sunitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:36:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-highlights-breadth-of-immuno-oncology-research-program-in-genitourinary-cancers-at-asco-gu/</loc>
		<lastmod>2025-03-08T04:36:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-increases-focus-on-advanced-prostate-cancer-expanding-immuno-oncology-program-with-three-new-phase-3-trials/</loc>
		<lastmod>2025-03-08T04:36:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-for-review-new-drug-application-nda-for-mercks-investigational-combination-of-imipenem-cilastatin-and-relebactam-and-supplemental-nda-snda-for-zerbaxa-ceftolozane-and/</loc>
		<lastmod>2025-03-08T04:36:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-recurrent-or-metastatic-head-a/</loc>
		<lastmod>2025-03-08T04:36:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-medicines-agency-adopts-positive-opinion-for-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-adults-with-metastatic-squamous-non-sm/</loc>
		<lastmod>2025-03-08T04:36:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-breakthrough-therapy-designation-from-fda-for-v114-the-companys-investigational-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-ch/</loc>
		<lastmod>2025-03-08T04:36:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2018-financial-results/</loc>
		<lastmod>2025-03-08T04:36:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2019-dividend/</loc>
		<lastmod>2025-03-08T04:36:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mary-ellen-coe-elected-to-merck-board-of-directors/</loc>
		<lastmod>2025-03-08T04:36:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-risk-of-death-by-31-percent-compared-to-chemotherapy-in-previously-treated-patients-with-advanced-esophageal-or-esophagogastric-junction-carcinom/</loc>
		<lastmod>2025-03-08T04:36:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2018-sales-and-earnings-conference-call-on-february-1/</loc>
		<lastmod>2025-03-08T04:36:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-accepts-sndas-for-pifeltro-doravirine-and-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate/</loc>
		<lastmod>2025-03-08T04:36:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-exercises-option-for-ngm-bios-investigational-insulin-sensitizer-ngm313-for-the-treatment-of-nash-and-type-2-diabetes/</loc>
		<lastmod>2025-03-08T04:36:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-five-new-approvals-in-japan-including-in-advanced-non-small-cell-lung-cancer-nsclc-as-adjuvant-therapy-for-melanoma-and-in-advanced-microsa/</loc>
		<lastmod>2025-03-08T04:36:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-at-the-37th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:36:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-three-new-approvals-in-japan/</loc>
		<lastmod>2025-03-08T04:36:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-initial-doses-of-investigational-biological-therapy-for-the-treatment-of-patients-with-severe-and-critical-covid-19/</loc>
		<lastmod>2025-03-08T04:36:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-statistically-significant-improvement-in-overall-survival-progression-free-survival-and-objective-response-rate/</loc>
		<lastmod>2025-03-08T04:36:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable/</loc>
		<lastmod>2025-03-08T04:36:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficien/</loc>
		<lastmod>2025-03-08T04:36:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-2020-evercore-isi-3rd-annual-healthconx-virtual-conference/</loc>
		<lastmod>2025-03-08T04:36:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-oncoimmune/</loc>
		<lastmod>2025-03-08T04:36:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-submits-applications-for-licensure-of-v114-the-companys-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-to-the-u-s-fda-and-european-medicines-agency/</loc>
		<lastmod>2025-03-08T04:36:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-patients-with-locally-recurrent-unresectable-or-metastatic-triple%e2%80%91negative-breast-cancer-whose/</loc>
		<lastmod>2025-03-08T04:36:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-advances-phase-3-trial-to-evaluate-investigational-islatravir-as-once-monthly-oral-prep-for-women-at-high-risk-for-acquiring-hiv-1/</loc>
		<lastmod>2025-03-08T04:36:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keynote-598-trial-evaluating-keytruda-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metastatic-non-small-cell-lung-cancer-to/</loc>
		<lastmod>2025-03-08T04:36:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrated-statistically-significant-improvement-in-progression-free-survival-pfs-overall-survival-os-and-objective-response-rate/</loc>
		<lastmod>2025-03-08T04:36:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-for-treatment-of-brca1-2-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/</loc>
		<lastmod>2025-03-08T04:36:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-bevacizumab-approved-in-the-eu-as-first-line-maintenance-treatment-for-hrd-positive-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/</loc>
		<lastmod>2025-03-08T04:36:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-velosbio/</loc>
		<lastmod>2025-03-08T04:36:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-its-extensive-infectious-diseases-and-vaccines-pipeline-and-portfolio-during-idweek-2020/</loc>
		<lastmod>2025-03-08T04:36:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-donates-500000-to-support-river-blindness-and-lymphatic-filariasis-elimination-efforts/</loc>
		<lastmod>2025-03-08T04:36:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-topline-results-from-two-additional-phase-3-adult-studies-evaluating-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine/</loc>
		<lastmod>2025-03-08T04:36:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-sanofi-to-present-three-new-studies-highlighting-combination-pediatric-vaccines-at-idweek-2020/</loc>
		<lastmod>2025-03-08T04:36:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl/</loc>
		<lastmod>2025-03-08T04:36:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-three-year-survival-data-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-and-updated-phase-1-2-data-for-investigational-quavonlimab-mk-1308-in-combination-with-key/</loc>
		<lastmod>2025-03-08T04:36:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-week-96-data-from-phase-2b-study-evaluating-islatravir-in-combination-with-doravirine-in-adults-with-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:36:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-issues-2019-2020-corporate-responsibility-report/</loc>
		<lastmod>2025-03-08T04:36:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-the-companys-diverse-hiv-portfolio-and-pipeline-at-hiv-glasgow-2020/</loc>
		<lastmod>2025-03-08T04:36:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-retirement-of-dr-roger-m-perlmutter-dr-dean-y-li-appointed-as-president-merck-research-laboratories/</loc>
		<lastmod>2025-03-08T04:36:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-locally-advanced-or-metastatic-esophageal-cancer/</loc>
		<lastmod>2025-03-08T04:36:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-supports-rabies-elimination-by-2030-on-world-rabies-day/</loc>
		<lastmod>2025-03-08T04:36:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-third-quarter-2020-sales-and-earnings-conference-call-on-october-27/</loc>
		<lastmod>2025-03-08T04:36:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-recommended-for-approval-in-eu-by-chmp-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/first-line-treatment-with-mercks-keytruda-pembrolizumab-doubled-five-year-survival-rate-31-9-versus-chemotherapy-16-3-in-certain-patients-with-metastatic-non-small-cell-lung-cance/</loc>
		<lastmod>2025-03-08T04:36:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-reduced-risk-of-death-by-31-vs-enzalutamide-or-abiraterone-for-men-with-brca1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-who-progressed-following-enzalutamide-or-abirat/</loc>
		<lastmod>2025-03-08T04:36:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-for-treatment-of-brca1-2-metastatic-castration-resistant-prostate-cancer-mcrpc/</loc>
		<lastmod>2025-03-08T04:36:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-promising-new-data-for-three-investigational-medicines-from-diverse-and-expansive-oncology-pipeline-at-esmo-virtual-congress-2020/</loc>
		<lastmod>2025-03-08T04:36:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-distant-metastasis-or-death-by-40-versus-placebo-as-adjuvant-treatment-in-resected-high-risk-stage-iii-melanoma/</loc>
		<lastmod>2025-03-08T04:36:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-present-first-time-data-from-two-studies-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-seven-different-tumor-types-at-esmo-virtual-congress-2020/</loc>
		<lastmod>2025-03-08T04:36:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-2020-cantor-fitzgerald-virtual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:36:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-investor-briefing-following-esmo-virtual-congress-2020/</loc>
		<lastmod>2025-03-08T04:36:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-improved-median-progression-free-survival-to-over-four-and-a-half-years-compared-to-13-8-months-with-placebo-for-patients-with-brca-mutated-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:36:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-18th-annual-virtual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:36:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/seattle-genetics-and-merck-announce-two-strategic-oncology-collaborations/</loc>
		<lastmod>2025-03-08T04:36:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-gefapixant-45-mg-twice-daily-significantly-decreased-cough-frequency-compared-to-placebo-at-week-12-and-24-in-patients-with-refractory-or-unexplained-chronic-cough/</loc>
		<lastmod>2025-03-08T04:36:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-topline-results-from-two-phase-3-adult-studies-evaluating-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-including-pivotal-trial/</loc>
		<lastmod>2025-03-08T04:36:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-citi-15th-annual-biopharma-virtual-conference/</loc>
		<lastmod>2025-03-08T04:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/biopharma-leaders-unite-to-stand-with-science/</loc>
		<lastmod>2025-03-08T04:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/</loc>
		<lastmod>2025-03-08T04:37:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-scientific-data-at-the-esmo-virtual-congress-2020-reflect-mercks-commitment-to-advancing-cancer-research-and-care/</loc>
		<lastmod>2025-03-08T04:37:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy-for-nonalcoholic-steatohepatitis-nash/</loc>
		<lastmod>2025-03-08T04:37:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-identigen/</loc>
		<lastmod>2025-03-08T04:37:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-overall-survival-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or/</loc>
		<lastmod>2025-03-08T04:37:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-worldwide-rights-to-vecoxan-brand-of-parasiticides-for-ruminant-portfolio/</loc>
		<lastmod>2025-03-08T04:37:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-two-us-regulatory-milestones-for-keytruda-pembrolizumab-in-triple-negative-breast-cancer-tnbc/</loc>
		<lastmod>2025-03-08T04:37:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2020-financial-results/</loc>
		<lastmod>2025-03-08T04:37:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-drug-application-for-vericiguat/</loc>
		<lastmod>2025-03-08T04:37:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2020-dividend/</loc>
		<lastmod>2025-03-08T04:37:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-to-mercks-novel-hif-2%ce%b1-inhibitor-mk-6482-for-treatment-of-certain-patients-with-von-hippel-lindau-disease-associated-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:37:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-second-line-treatment-of-patients-with-relapsed-or-refractory-classical/</loc>
		<lastmod>2025-03-08T04:37:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-receives-u-s-fda-approval-of-bravecto-fluralaner-monthly-chews/</loc>
		<lastmod>2025-03-08T04:37:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-for-germline-brca-mutated-metastatic-pancreatic-cancer/</loc>
		<lastmod>2025-03-08T04:37:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-organon-co-general-counsel/</loc>
		<lastmod>2025-03-08T04:37:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-new-analyses-showing-additional-safety-and-efficacy-data-for-investigational-islatravir-in-combination-with-doravirine-in-adults-with-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:37:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-receive-complete-response-letter-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma/</loc>
		<lastmod>2025-03-08T04:37:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2020-sales-and-earnings-conference-call-on-july-31/</loc>
		<lastmod>2025-03-08T04:37:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-bio-announce-closing-of-collaboration-and-licensing-transaction/</loc>
		<lastmod>2025-03-08T04:37:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-u-s-rights-to-sentinel-brand-of-combination-parasiticides-for-companion-animals/</loc>
		<lastmod>2025-03-08T04:37:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-cscc-that-is-not-curable-by-surgery-or-radiat/</loc>
		<lastmod>2025-03-08T04:37:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer/</loc>
		<lastmod>2025-03-08T04:37:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-that-v114-its-investigational-15-valent-pneumococcal-conjugate-vaccine-met-safety-and-immunogenicity-objectives-in-initial-phase-3-studies-in-adults/</loc>
		<lastmod>2025-03-08T04:37:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-underscores-commitment-to-hiv-with-new-data-analyses-to-be-presented-at-aids-2020-virtual/</loc>
		<lastmod>2025-03-08T04:37:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-second-biomarker-based-indication-for-mercks-keytruda-pembrolizumab-regardless-of-tumor-type/</loc>
		<lastmod>2025-03-08T04:37:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-quantified-ag/</loc>
		<lastmod>2025-03-08T04:37:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-themis/</loc>
		<lastmod>2025-03-08T04:37:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-for-second-line-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-whose-tumors-express-pd-l1/</loc>
		<lastmod>2025-03-08T04:37:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-pfizers-sglt2-inhibitor-steglatro-ertugliflozin-meets-primary-endpoint-in-vertis-cv-trial-for-patients-with-type-2-diabetes-and-atherosclerotic-cardiovascular-disease/</loc>
		<lastmod>2025-03-08T04:37:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-prices-4-5-billion-debt-offering/</loc>
		<lastmod>2025-03-08T04:37:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers/</loc>
		<lastmod>2025-03-08T04:37:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-call-for-proposals-for-second-cohort-of-safer-childbirth-cities-expanding-maternal-health-support-across-us-cities/</loc>
		<lastmod>2025-03-08T04:37:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia-habp-vabp/</loc>
		<lastmod>2025-03-08T04:37:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-361-trial-evaluating-keytruda-pembrolizumab-as-monotherapy-and-in-combination-with-chemotherapy-in-patients-with-advanced-or-metastatic-urothelial-carc/</loc>
		<lastmod>2025-03-08T04:37:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-clinically-meaningful-tumor-response-rates-in-unresectable-hepatocellular-carcinoma-and-advanced-renal-cell-carc/</loc>
		<lastmod>2025-03-08T04:37:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-for-first-line-maintenance-treatment-of-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/</loc>
		<lastmod>2025-03-08T04:37:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2020-dividend/</loc>
		<lastmod>2025-03-08T04:37:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-superior-to-standard-of-care-chemotherapy-in-patients-with-msi-h-colorectal-cancer/</loc>
		<lastmod>2025-03-08T04:37:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-themis/</loc>
		<lastmod>2025-03-08T04:37:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/iavi-and-merck-collaborate-to-develop-vaccine-against-sars-cov-2/</loc>
		<lastmod>2025-03-08T04:37:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-bio-collaborate-to-advance-development-of-novel-antiviral-candidate-eidd-2801/</loc>
		<lastmod>2025-03-08T04:37:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-by-fda-for-treatment-of-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer-that-has-progressed-following-prior-treatment-with-enzalutamide-or-abiratero/</loc>
		<lastmod>2025-03-08T04:37:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-announce-multiple-scientific-efforts-to-combat-covid-19/</loc>
		<lastmod>2025-03-08T04:37:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-ubs-virtual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:37:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-organon-co-chief-financial-officer-and-chief-information-officer/</loc>
		<lastmod>2025-03-08T04:37:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/infectious-disease-connect-and-ilum-health-solutions-combine-to-advance-precision-treatment-of-infectious-diseases-and-antimicrobial-stewardship/</loc>
		<lastmod>2025-03-08T04:37:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-demonstrated-statistically-significant-improvement-in-progression-free-survival-versus-chemotherapy-in-certain-patients-with-metastatic/</loc>
		<lastmod>2025-03-08T04:37:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-combination-data-for-mercks-keytruda-pembrolizumab-demonstrated-clinical-benefit-in-stage-iii-non-small-cell-lung-cancer-nsclc-and-reinforce-long-term-survival-in-metastatic-nsc/</loc>
		<lastmod>2025-03-08T04:37:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-novel-hif-2%ce%b1-inhibitor-showed-an-objective-response-rate-of-nearly-30-in-patients-with-von-hippel-lindau-vhl-disease-associated-clear-cell-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:37:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-superior-to-brentuximab-vedotin-bv-a-standard-of-care-in-patients-with-classical-hodgkin-lymphoma-chl-in-head-to-head-phase-3-trial/</loc>
		<lastmod>2025-03-08T04:37:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-by-fda-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:37:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-to-acquire-u-s-rights-to-sentinel-brand-of-combination-parasiticides-for-companion-animals/</loc>
		<lastmod>2025-03-08T04:37:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-its-broad-oncology-portfolio-and-pipeline-at-the-asco20-virtual-scientific-program/</loc>
		<lastmod>2025-03-08T04:37:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-bofa-securities-2020-health-care-conference/</loc>
		<lastmod>2025-03-08T04:37:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-virtual-2020-annual-shareholders-meeting/</loc>
		<lastmod>2025-03-08T04:37:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-commits-additional-10-million-to-covid-19-relief-efforts-to-help-disparately-impacted-patients-and-communities/</loc>
		<lastmod>2025-03-08T04:37:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/results-of-phase-3-trial-evaluating-the-efficacy-and-safety-of-mercks-recarbrio-imipenem-cilastatin-and-relebactam-versus-piperacillin-and-tazobactam-in-adult-patients-with-habp/</loc>
		<lastmod>2025-03-08T04:37:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2020-financial-results/</loc>
		<lastmod>2025-03-08T04:37:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-approved-adult-indications/</loc>
		<lastmod>2025-03-08T04:37:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/first-clinical-outcomes-evaluating-six-week-dosing-schedule-for-mercks-keytruda-pembrolizumab-presented-at-aacr-virtual-annual-meeting-i/</loc>
		<lastmod>2025-03-08T04:37:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-resubmits-supplemental-biologics-license-applications-sblas-for-keytruda-pembrolizumab-six-week-dosing-schedule/</loc>
		<lastmod>2025-03-08T04:37:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-demonstrated-overall-survival-benefit-in-phase-3-profound-trial-for-brca1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:37:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-institute-for-systems-biology-collaborate-to-define-molecular-mechanisms-of-sars-cov-2-infection-and-identify-potential-prognostic-biomarkers/</loc>
		<lastmod>2025-03-08T04:37:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-us-launch-of-ontruzant-trastuzumab-dttb-a-biosimilar-of-herceptin-trastuzumab/</loc>
		<lastmod>2025-03-08T04:37:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-broadens-patient-support-and-assistance-programs-as-part-of-overall-covid-19-relief-efforts/</loc>
		<lastmod>2025-03-08T04:37:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-3m-commitment-to-address-critical-maternal-health-needs-during-covid-19-pandemic/</loc>
		<lastmod>2025-03-08T04:37:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/koselugo-selumetinib-approved-by-fda-for-pediatric-patients-two-years-and-older-with-neurofibromatosis-type-1-and-symptomatic-inoperable-plexiform-neurofibromas/</loc>
		<lastmod>2025-03-08T04:37:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keytruda-pembrolizumab-significantly-improved-progression-free-survival-as-first-line-treatment-for-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficien/</loc>
		<lastmod>2025-03-08T04:37:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-priority-review-from-fda-for-second-application-for-keytruda-pembrolizumab-based-on-biomarker-regardless-of-tumor-type/</loc>
		<lastmod>2025-03-08T04:37:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/investigational-drug-vericiguat-significantly-reduced-the-risk-of-the-composite-endpoint-of-heart-failure-hospitalization-or-cardiovascular-death-compared-to-placebo-when-given-in-combination-with-a/</loc>
		<lastmod>2025-03-08T04:37:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/medical-professionals-across-merck-co-inc-pfizer-inc-and-eli-lilly-and-company-activate-to-support-health-systems-first-responders-and-patients-amid-covid-19-pandemic/</loc>
		<lastmod>2025-03-08T04:37:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2020-sales-and-earnings-conference-call-on-april-28/</loc>
		<lastmod>2025-03-08T04:37:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-donates-a-half-a-million-masks-to-support-covid-19-emergency-response-in-new-york-city/</loc>
		<lastmod>2025-03-08T04:37:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-donate-300000-masks-to-new-jersey-for-covid-19-emergency-response/</loc>
		<lastmod>2025-03-08T04:37:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/scientists-from-merck-and-the-walter-and-eliza-hall-institute-of-medical-research-discover-novel-class-of-candidate-anti-malaria-agents-that-block-multiple-stages-of-the-lifecycle-of-the-parasite/</loc>
		<lastmod>2025-03-08T04:37:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/update-on-phase-3-gy004-for-cediranib-and-lynparza-olaparib-in-platinum-sensitive-relapsed-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:37:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant-an-investigational-treatment-for-refractory-or-unexplained-chronic-cough/</loc>
		<lastmod>2025-03-08T04:37:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-recommends-rejection-of-trc-capitals-mini-tender-offer/</loc>
		<lastmod>2025-03-08T04:37:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-progression-free-survival-compared-with-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-ch/</loc>
		<lastmod>2025-03-08T04:37:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-new-data-from-broad-hiv-program-at-croi-2020/</loc>
		<lastmod>2025-03-08T04:37:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-complete-response-letter-from-the-us-fda-for-supplemental-biologics-license-applications-sblas-for-keytruda-pembrolizumab-six-week-dosing-schedule/</loc>
		<lastmod>2025-03-08T04:37:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-cowen-health-care-conference/</loc>
		<lastmod>2025-03-08T04:37:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-treatment-for-metastatic-triple-negative-breast-ca/</loc>
		<lastmod>2025-03-08T04:37:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ervebo-ebola-zaire-vaccine-live-now-registered-in-four-african-countries-within-90-days-of-reference-country-approval-and-who-prequalification/</loc>
		<lastmod>2025-03-08T04:37:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2019-financial-results/</loc>
		<lastmod>2025-03-08T04:37:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-approval-for-belsomra-suvorexant-c-iv-label-update-to-include-findings-from-study-of-insomnia-in-patients-with-mild-to-moderate-alzheimers-disease/</loc>
		<lastmod>2025-03-08T04:37:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-for-review-supplemental-new-drug-application-snda-for-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associat/</loc>
		<lastmod>2025-03-08T04:37:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-focus-on-key-growth-pillars-through-spinoff-of-womens-health-trusted-legacy-brands-and-biosimilars-products-into-new-company-newco/</loc>
		<lastmod>2025-03-08T04:37:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2020-dividend/</loc>
		<lastmod>2025-03-08T04:37:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/dr-christine-seidman-and-kathy-warden-elected-to-merck-board-of-directors/</loc>
		<lastmod>2025-03-08T04:37:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-hrr-mutated-metastatic-castration-resistant-prostate-cancer-and-grants-priority-review/</loc>
		<lastmod>2025-03-08T04:37:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older/</loc>
		<lastmod>2025-03-08T04:37:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-with-or-without-papillary-tumors-wh/</loc>
		<lastmod>2025-03-08T04:37:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-as-first-line-maintenance-with-bevacizumab-in-advanced-ovarian-cancer-and-grants-priority-review/</loc>
		<lastmod>2025-03-08T04:37:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-arqule/</loc>
		<lastmod>2025-03-08T04:37:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-treatment-for-extensive-st/</loc>
		<lastmod>2025-03-08T04:37:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:37:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2019-sales-and-earnings-conference-call-on-february-5/</loc>
		<lastmod>2025-03-08T04:37:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-establishes-strategic-oncology-collaboration-with-taiho-and-astex/</loc>
		<lastmod>2025-03-08T04:37:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-receives-special-approval-for-emergency-in-japan/</loc>
		<lastmod>2025-03-08T04:37:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-patients-with-unresectable-advanced-or-recurrent-endometrial-carcinoma-that-progressed-after-cancer-chemotherapy/</loc>
		<lastmod>2025-03-08T04:37:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19/</loc>
		<lastmod>2025-03-08T04:37:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-u-k-government-to-purchase-additional-1-75-million-courses-of-molnupiravir/</loc>
		<lastmod>2025-03-08T04:37:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-following-surgery/</loc>
		<lastmod>2025-03-08T04:37:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-individuals-18-years-of-age-and-older/</loc>
		<lastmod>2025-03-08T04:37:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-publication-of-phase-3-study-of-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-in-the-new-england-journal-of-medicine/</loc>
		<lastmod>2025-03-08T04:37:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-issues-1-billion-inaugural-sustainability-bond/</loc>
		<lastmod>2025-03-08T04:37:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:37:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-additional-150m-investment-through-2025-to-help-end-maternal-mortality-inequities/</loc>
		<lastmod>2025-03-08T04:37:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-prices-8-0-billion-debt-offering-2/</loc>
		<lastmod>2025-03-08T04:37:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/</loc>
		<lastmod>2025-03-08T04:37:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-pause-in-enrollment-for-two-phase-3-clinical-trials-of-investigational-once-monthly-oral-islatravir-for-pre-exposure-prophylaxis-prep-of-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:37:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-statement-on-positive-fda-advisory-committee-vote-for-investigational-oral-antiviral-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults/</loc>
		<lastmod>2025-03-08T04:37:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/</loc>
		<lastmod>2025-03-08T04:37:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2022-dividend/</loc>
		<lastmod>2025-03-08T04:37:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-radically-unresectable-advanced-or-recurrent-esophageal-car/</loc>
		<lastmod>2025-03-08T04:37:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-as-adjuvant-treatment-in-brca-mutated-her2-negative-high-risk-early-breast-cancer-and-grants-prior/</loc>
		<lastmod>2025-03-08T04:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/</loc>
		<lastmod>2025-03-08T04:38:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-adult-patients-with-advanced-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:38:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-4th-annual-evercore-isi-healthconx-conference/</loc>
		<lastmod>2025-03-08T04:38:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-2-clinical-trial-of-once-weekly-investigational-combination-of-mk-8507-and-islatravir-for-the-treatment-of-people-living-with-hiv-1/</loc>
		<lastmod>2025-03-08T04:38:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-tender-offer-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery/</loc>
		<lastmod>2025-03-08T04:38:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-to-present-phase-3-data-for-molnupiravir-an-investigational-oral-covid-19-antiviral-medicine-at-american-society-of-tropical-medicine-and-hygiene-astmh-2021-annual-meeting/</loc>
		<lastmod>2025-03-08T04:38:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-initiation-of-phase-3-study-evaluating-verquvo-vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-who-have-not-had-a-recent-worsening-heart-failure/</loc>
		<lastmod>2025-03-08T04:38:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-japanese-government-to-purchase-1-6-million-courses-of-molnupiravir-an-investigational-oral-covid-19-antiviral-medicine-upon-authorization-or-approval/</loc>
		<lastmod>2025-03-08T04:38:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-u-s-government-to-purchase-1-4-million-additional-courses-of-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-a/</loc>
		<lastmod>2025-03-08T04:38:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-receipt-of-antitrust-clearance-in-germany-and-austria-relating-to-tender-offer-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-research-for-keytruda-pembrolizumab-at-society-for-melanoma-research-smr-2021-congress-reinforces-mercks-commitment-to-patients-with-melanoma-across-stages-of-disease/</loc>
		<lastmod>2025-03-08T04:38:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/</loc>
		<lastmod>2025-03-08T04:38:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2021-financial-results/</loc>
		<lastmod>2025-03-08T04:38:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-withdrawal-and-refiling-under-the-hart-scott-rodino-act-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-new-data-from-ongoing-phase-2b-clinical-trial-evaluating-efficacy-and-safety-of-investigational-islatravir-in-combination-with-doravirine-through-144-weeks-for-hiv-1-treatment-at-eacs-2/</loc>
		<lastmod>2025-03-08T04:38:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/gilead-and-merck-initiate-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-lenacapavir-and-investigational-islatravir-for-hiv-1-treatment-in-virologically-suppressed-adul/</loc>
		<lastmod>2025-03-08T04:38:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/the-medicines-patent-pool-mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countri/</loc>
		<lastmod>2025-03-08T04:38:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-initiation-of-a-rolling-review-by-the-european-medicines-agency-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-covid-19-in-adults/</loc>
		<lastmod>2025-03-08T04:38:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-oral-fixed-dose-combination-of-doravirine-islatravir-for-the-treatment-of-people-with-hiv-1/</loc>
		<lastmod>2025-03-08T04:38:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/cdc-acip-unanimously-votes-to-provisionally-recommend-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-series-with-pneumovax-23-pneumococcal-vaccine-polyvalen/</loc>
		<lastmod>2025-03-08T04:38:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast/</loc>
		<lastmod>2025-03-08T04:38:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-issues-voluntary-nationwide-recall-of-cubicin-daptomycin-for-injection-500-mg-lot-934778-due-to-presence-of-particulate-matter-identified-as-glass-particles/</loc>
		<lastmod>2025-03-08T04:38:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-receive-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-two-different-types-of-cancer/</loc>
		<lastmod>2025-03-08T04:38:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older/</loc>
		<lastmod>2025-03-08T04:38:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose-tum/</loc>
		<lastmod>2025-03-08T04:38:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-begins-tender-offer-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/</loc>
		<lastmod>2025-03-08T04:38:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-emmy-nominated-actress-yvonne-orji-unveil-uncovering-tnbc-highlighting-the-challenges-faced-by-black-women-diagnosed-with-triple-negative-breast-cancer/</loc>
		<lastmod>2025-03-08T04:38:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-acceleron-pharma-inc/</loc>
		<lastmod>2025-03-08T04:38:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/</loc>
		<lastmod>2025-03-08T04:38:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-thomas-h-glocer-as-independent-lead-director/</loc>
		<lastmod>2025-03-08T04:38:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-thomas-h-glocer-as-independent-lead-director/</loc>
		<lastmod>2025-03-08T04:38:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-significantly-delayed-disease-progression-in-patients-regardless-of-biomarker-status-in-propel-phase-3-trial-in-first-line-metastatic-castrati/</loc>
		<lastmod>2025-03-08T04:38:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keytruda-pembrolizumab-met-primary-endpoint-of-overall-survival-os-in-patients-with-advanced-hepatocellular-carcinoma-previously-treated-with-sorafenib/</loc>
		<lastmod>2025-03-08T04:38:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-reduced-risk-of-death-by-one-third-versus-chemotherapy-with-or-without-bevacizumab-as-first-line-treatment/</loc>
		<lastmod>2025-03-08T04:38:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-whos/</loc>
		<lastmod>2025-03-08T04:38:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breas/</loc>
		<lastmod>2025-03-08T04:38:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-rfs-in-patients-with-resected-high-risk-stage-ii-melanoma-compared-to-placebo-in-the-adjuvant-setting/</loc>
		<lastmod>2025-03-08T04:38:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-19th-annual-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:38:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-its-broad-oncology-portfolio-and-pipeline-at-esmo-2021-including-in-earlier-stages-of-cancer/</loc>
		<lastmod>2025-03-08T04:38:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection/</loc>
		<lastmod>2025-03-08T04:38:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-locally-advanced-unresectable-or-metastatic-esophageal-or-ga/</loc>
		<lastmod>2025-03-08T04:38:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan-2/</loc>
		<lastmod>2025-03-08T04:38:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/</loc>
		<lastmod>2025-03-08T04:38:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/leslie-a-brun-resigns-from-merck-board-of-directors/</loc>
		<lastmod>2025-03-08T04:38:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-met-key-immunogenicity-and-safety-endpoints-in-phase-3-pivotal-trial-evaluating-use-in-infants-pneu-ped-v114-029/</loc>
		<lastmod>2025-03-08T04:38:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:38:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%ce%b1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease/</loc>
		<lastmod>2025-03-08T04:38:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-as-adjuvant-therapy-in-certain-patients-with-renal-cell-carcinoma-rcc-foll/</loc>
		<lastmod>2025-03-08T04:38:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-single-agent-for-certain-patients-with-msi-h-dmmr-advanced-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:38:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-appointment-of-cristal-n-downing-as-chief-communications-public-affairs-officer/</loc>
		<lastmod>2025-03-08T04:38:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-prolonged-recurrence-free-survival-rfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-stage-ii-resected-high-risk-melanoma-in/</loc>
		<lastmod>2025-03-08T04:38:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2021-dividend/</loc>
		<lastmod>2025-03-08T04:38:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2021-financial-results/</loc>
		<lastmod>2025-03-08T04:38:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued/</loc>
		<lastmod>2025-03-08T04:38:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-355-trial-met-primary-endpoint-of-overall-survival-os-in-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-cps-%e2%89%a510/</loc>
		<lastmod>2025-03-08T04:38:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/verquvo-vericiguat-approved-in-the-european-union/</loc>
		<lastmod>2025-03-08T04:38:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-patients-with-certain-types-of-advanced-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:38:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/</loc>
		<lastmod>2025-03-08T04:38:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-new-data-from-ongoing-phase-2a-clinical-trial-evaluating-the-safety-tolerability-and-pharmacokinetics-of-investigational-once-monthly-oral-islatravir-for-hiv-1-prevention-at-ias-2021/</loc>
		<lastmod>2025-03-08T04:38:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-presentation-of-new-data-from-broad-hiv-program-at-ias-2021/</loc>
		<lastmod>2025-03-08T04:38:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-showed-statistically-significant-event-free-survival-efs-result-versus-neoadjuvant-chemo/</loc>
		<lastmod>2025-03-08T04:38:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/interim-results-from-phase-2-3-studies-of-molnupiravir-an-investigational-oral-antiviral-therapeutic-for-mild-to-moderate-covid-19-presented-at-the-european-congress-of-clinical-microbiology-i/</loc>
		<lastmod>2025-03-08T04:38:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-third-line-gastric-cancer-in-the-us/</loc>
		<lastmod>2025-03-08T04:38:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma-cscc/</loc>
		<lastmod>2025-03-08T04:38:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-certain-patients-with-esophageal-cancer-or-her2-negative-gastroesophageal-junction-gej-adenocarcinom/</loc>
		<lastmod>2025-03-08T04:38:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2021-sales-and-earnings-conference-call-on-july-29/</loc>
		<lastmod>2025-03-08T04:38:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-china-for-the-treatment-of-certain-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:38:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-appoints-michael-klobuchar-chief-strategy-officer/</loc>
		<lastmod>2025-03-08T04:38:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-guggenheim-biopharma-strategy-series/</loc>
		<lastmod>2025-03-08T04:38:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-826-trial-met-dual-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-patients-with-persistent-recurrent-or-metastatic-cervical-cancer/</loc>
		<lastmod>2025-03-08T04:38:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/msd-animal-health-to-acquire-assets-of-lic-automation-ltd/</loc>
		<lastmod>2025-03-08T04:38:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19/</loc>
		<lastmod>2025-03-08T04:38:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-the-kenneth-c-frazier-award-for-maternal-health-equity-to-accelerate-progress-towards-improved-birth-outcomes-for-all/</loc>
		<lastmod>2025-03-08T04:38:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-reduced-the-risk-of-invasive-disease-recurrence-or-death-by-42-versus-placebo-in-adjuvant-treatment-of-patients-with-germline-brca-mutations-and-high-risk-her2-negative-early/</loc>
		<lastmod>2025-03-08T04:38:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-data-on-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-sunitinib-in-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-from-pivotal-phase-3-clear-keynote-5/</loc>
		<lastmod>2025-03-08T04:38:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-completion-of-organon-co-spinoff/</loc>
		<lastmod>2025-03-08T04:38:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-given-after-surgery-reduced-the-risk-of-disease-recurrence-or-death-by-32-versus-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:38:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2021-dividend/</loc>
		<lastmod>2025-03-08T04:38:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-sanofis-first-and-only-six-in-one-pediatric-combination-vaccine-now-available-in-the-united-states/</loc>
		<lastmod>2025-03-08T04:38:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-topline-results-from-pneu-direction-v114-027-and-pneu-plan-v114-024-phase-3-pediatric-studies-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-va/</loc>
		<lastmod>2025-03-08T04:38:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-certain-patients-with-esophageal-cancer-or-her2-negative-gastroe/</loc>
		<lastmod>2025-03-08T04:38:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-declares-record-date-and-dividend-for-the-organon-co-spinoff/</loc>
		<lastmod>2025-03-08T04:38:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc/</loc>
		<lastmod>2025-03-08T04:38:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-receive-priority-review-from-fda-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-applications-for-advanced-renal-cell-carcinoma-and-for-advanced-endometrial-carcinom/</loc>
		<lastmod>2025-03-08T04:38:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-highlights-scientific-data-at-2021-asco-annual-meeting-across-more-than-20-cancer-types-from-broad-oncology-research-program/</loc>
		<lastmod>2025-03-08T04:38:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-hosts-organon-investor-day-outlining-new-companys-vision-focus-and-business-model-for-sustained-growth/</loc>
		<lastmod>2025-03-08T04:38:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-combined-with-trastuzumab-and-chemotherapy-as-first-line-treatment-in-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-g/</loc>
		<lastmod>2025-03-08T04:38:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2021-financial-results/</loc>
		<lastmod>2025-03-08T04:38:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-accelerates-climate-goals-announces-carbon-neutrality-in-operations-by-2025/</loc>
		<lastmod>2025-03-08T04:38:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/amid-humanitarian-crisis-in-india-merck-announces-voluntary-licensing-agreements-with-five-indian-generics-manufacturers-to-accelerate-and-expand-global-access-to-molnupiravir-an-investigational-ora/</loc>
		<lastmod>2025-03-08T04:38:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-investor-briefing-featuring-organon-on-may-3/</loc>
		<lastmod>2025-03-08T04:38:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-expands-safer-childbirth-cities-initiative-to-20th-community-led-project-advancing-maternal-health-equity-during-black-maternal-health-week/</loc>
		<lastmod>2025-03-08T04:38:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/</loc>
		<lastmod>2025-03-08T04:38:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/</loc>
		<lastmod>2025-03-08T04:38:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery/</loc>
		<lastmod>2025-03-08T04:38:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/organon-announces-pricing-of-senior-notes-offering/</loc>
		<lastmod>2025-03-08T04:38:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-acquisition-of-alydia-health-on-behalf-of-its-planned-spinoff-of-organon/</loc>
		<lastmod>2025-03-08T04:38:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-pandion-therapeutics/</loc>
		<lastmod>2025-03-08T04:38:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/organon-announces-proposed-senior-notes-offering/</loc>
		<lastmod>2025-03-08T04:38:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-complete-response-letter-from-us-fda-for-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-tnb/</loc>
		<lastmod>2025-03-08T04:38:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-updated-label-of-keytruda-pembrolizumab-to-include-results-of-phase-3-keynote-361-trial-in-certain-adult-patients-with-locally-advanced-or-metastati/</loc>
		<lastmod>2025-03-08T04:38:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-appoints-caroline-litchfield-chief-financial-officer/</loc>
		<lastmod>2025-03-08T04:38:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2021-sales-and-earnings-conference-call-on-april-29/</loc>
		<lastmod>2025-03-08T04:38:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-significantly-improved-progression-free-survival-and-overall-survival-versus-chemotherapy-in-patients-with-advanced-endometrial-cancer-fo/</loc>
		<lastmod>2025-03-08T04:38:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-platinum-and-fluoropyrimidine-based-chemotherapy-for-treatment-of-certain-patients-with-locally-advanced-or-metastatic-esophageal-or-g/</loc>
		<lastmod>2025-03-08T04:38:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-and-pediatric-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl/</loc>
		<lastmod>2025-03-08T04:38:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-filing-of-form-10-registration-statement-in-connection-with-planned-spinoff-of-organon-co/</loc>
		<lastmod>2025-03-08T04:38:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-drug-application-for-hif-2%ce%b1-inhibitor-belzutifan-mk-6482/</loc>
		<lastmod>2025-03-08T04:38:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mike-nally-to-leave-merck-frank-clyburn-to-lead-all-merck-human-health/</loc>
		<lastmod>2025-03-08T04:38:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-results-from-phase-1-trial-evaluating-investigational-islatravir-subdermal-implant-for-the-prevention-of-hiv-1-infection-at-croi-2021/</loc>
		<lastmod>2025-03-08T04:38:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-long-acting-investigational-treatment-combinations-of-lenacapavir-and-islatravir-in-hiv-2/</loc>
		<lastmod>2025-03-08T04:38:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-host-investor-briefing-to-discuss-broad-hiv-development-program-and-newly-announced-collaboration-with-gilead/</loc>
		<lastmod>2025-03-08T04:38:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-barclays-global-healthcare-conference-2/</loc>
		<lastmod>2025-03-08T04:38:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-begins-tender-offer-to-acquire-pandion-therapeutics/</loc>
		<lastmod>2025-03-08T04:38:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/</loc>
		<lastmod>2025-03-08T04:38:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-help-produce-johnson-barda-to-provide-merck-with-funding-to-expand-mercks-manufacturing-capacity-for-covid-19-vaccines-and-medicines/</loc>
		<lastmod>2025-03-08T04:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-various-hiv-research-and-development-programs-at-croi-2021/</loc>
		<lastmod>2025-03-08T04:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-accepts-mercks-gefapixant-new-drug-application-for-review/</loc>
		<lastmod>2025-03-08T04:39:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us/</loc>
		<lastmod>2025-03-08T04:39:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fifth-round-of-global-grants-to-tackle-maternal-mortality-and-promote-health-equity-worldwide/</loc>
		<lastmod>2025-03-08T04:39:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-pandion-therapeutics/</loc>
		<lastmod>2025-03-08T04:39:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-poultry-sense-limited/</loc>
		<lastmod>2025-03-08T04:39:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/independent-data-monitoring-committee-concludes-olympia-trial-of-lynparza-olaparib-crossed-superiority-boundary-for-invasive-disease-free-survival-vs-placebo-at-planned-interim-analysis/</loc>
		<lastmod>2025-03-08T04:39:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-cowen-41st-annual-health-care-conference/</loc>
		<lastmod>2025-03-08T04:39:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2020-financial-results/</loc>
		<lastmod>2025-03-08T04:39:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrated-superior-progression-free-survival-pfs-and-overall-survival-os-versus-sunitinib-as-first-line-treatment-for-patients-wit/</loc>
		<lastmod>2025-03-08T04:39:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/kenneth-c-frazier-to-retire-as-merck-ceo-board-elects-robert-m-davis-as-successor-frazier-to-continue-as-executive-chairman/</loc>
		<lastmod>2025-03-08T04:39:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-expanded-approval-of-keytruda-pembrolizumab-in-certain-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/</loc>
		<lastmod>2025-03-08T04:39:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/dr-stephen-mayo-elected-to-merck-board-of-directors/</loc>
		<lastmod>2025-03-08T04:39:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-results-from-head-to-head-phase-3-keynote-598-trial-evaluating-keytruda-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metasta/</loc>
		<lastmod>2025-03-08T04:39:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-cohort-of-safer-childbirth-cities-organizations-committed-to-improving-maternal-health-equity-and-reducing-preventable-maternal-deaths-in-the-us/</loc>
		<lastmod>2025-03-08T04:39:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-results-from-head-to-head-phase-3-keynote-598-trial-evaluating-keytruda-pembrolizumab-in-combination-with-ipilimumab-versus-keytruda-monotherapy-in-certain-patients-with-metasta/</loc>
		<lastmod>2025-03-08T04:39:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colore/</loc>
		<lastmod>2025-03-08T04:39:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-interim-findings-from-phase-2a-clinical-trial-evaluating-investigational-once-monthly-oral-islatravir-for-the-prevention-of-hiv-1-infection-at-hivr4p-2021/</loc>
		<lastmod>2025-03-08T04:39:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-u-s-fda-approval-of-verquvo-vericiguat/</loc>
		<lastmod>2025-03-08T04:39:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/</loc>
		<lastmod>2025-03-08T04:39:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:39:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2020-sales-and-earnings-conference-call-on-february-4/</loc>
		<lastmod>2025-03-08T04:39:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older/</loc>
		<lastmod>2025-03-08T04:39:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-goldman-sachs-healthcare-ceos-unscripted-conference/</loc>
		<lastmod>2025-03-08T04:39:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:39:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer/</loc>
		<lastmod>2025-03-08T04:39:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/astellas-seagen-and-merck-announce-fda-acceptance-of-supplemental-biologics-license-applications-for-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-for-the-first-line-trea/</loc>
		<lastmod>2025-03-08T04:39:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/</loc>
		<lastmod>2025-03-08T04:39:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/astrazeneca-and-merck-provide-update-on-us-regulatory-review-of-lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-as-treatment-of-metastatic-castration-resistant/</loc>
		<lastmod>2025-03-08T04:39:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-data-from-its-hematology-portfolio-and-promising-pipeline-at-the-64th-american-society-of-hematology-ash-annual-meeting/</loc>
		<lastmod>2025-03-08T04:39:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-begins-tender-offer-to-acquire-imago-biosciences-inc/</loc>
		<lastmod>2025-03-08T04:39:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-859-trial-met-primary-endpoint-of-overall-survival-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma/</loc>
		<lastmod>2025-03-08T04:39:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2023-dividend/</loc>
		<lastmod>2025-03-08T04:39:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-5th-annual-evercore-isi-healthconx-conference/</loc>
		<lastmod>2025-03-08T04:39:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-imago-biosciences-inc/</loc>
		<lastmod>2025-03-08T04:39:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-receives-positive-opinion-from-eu-chmp-as-treatment-for-certain-patients-with-metastatic-castration-resistant-p/</loc>
		<lastmod>2025-03-08T04:39:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2022-financial-results/</loc>
		<lastmod>2025-03-08T04:39:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/reductions-in-certain-types-of-hpv-related-cervical-and-non-cervical-diseases-in-women-and-men-observed-with-real-world-use-of-mercks-gardasil-in-systematic-literature-review-of-138-studies/</loc>
		<lastmod>2025-03-08T04:39:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-expands-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-indication-to-include-infants-children-and-adolescents/</loc>
		<lastmod>2025-03-08T04:39:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/robert-m-davis-to-succeed-kenneth-c-frazier-as-chairman-of-merck/</loc>
		<lastmod>2025-03-08T04:39:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-prevymis-demonstrates-efficacy-in-phase-3-study-for-prevention-of-cytomegalovirus-disease-in-adults-after-kidney-transplantation/</loc>
		<lastmod>2025-03-08T04:39:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine/</loc>
		<lastmod>2025-03-08T04:39:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-the-bill-melinda-gates-medical-research-institute-announce-licensing-agreement-for-novel-tuberculosis-antibiotic-candidates/</loc>
		<lastmod>2025-03-08T04:39:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-top-line-results-from-pivotal-phase-3-stellar-trial-evaluating-sotatercept-for-the-treatment-of-adults-with-pulmonary-arterial-hypertension-pah/</loc>
		<lastmod>2025-03-08T04:39:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-recognized-on-fortunes-2022-change-the-world-list-for-expanding-access-to-hpv-vaccines/</loc>
		<lastmod>2025-03-08T04:39:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-court-of-appeals-for-the-federal-circuit-rules-in-favor-of-merck-in-sitagliptin-dihydrogen-phosphate-patent-lawsuit/</loc>
		<lastmod>2025-03-08T04:39:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-new-clinical-and-non-clinical-studies-of-lagevrio-molnupiravir/</loc>
		<lastmod>2025-03-08T04:39:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-minority-investment-in-leeo-precision-farming/</loc>
		<lastmod>2025-03-08T04:39:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-third-quarter-2022-sales-and-earnings-conference-call-october-27/</loc>
		<lastmod>2025-03-08T04:39:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-to-acquire-vence/</loc>
		<lastmod>2025-03-08T04:39:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-four-new-approvals-in-japan-including-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc/</loc>
		<lastmod>2025-03-08T04:39:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-district-court-rules-in-favor-of-merck-in-sitagliptin-phosphate-patent-lawsuit/</loc>
		<lastmod>2025-03-08T04:39:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-china-as-first-line-maintenance-treatment-with-bevacizumab-for-homologous-recombination-deficient-hrd-positive-advanced-ovarian-cancer/</loc>
		<lastmod>2025-03-08T04:39:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-infants-and-children/</loc>
		<lastmod>2025-03-08T04:39:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-initiate-new-phase-3-clinical-program-with-lower-dose-of-daily-oral-islatravir-in-combination-with-doravirine-for-treatment-of-people-with-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:39:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/five-year-data-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-sustained-survival-benefit-versus-chemotherapy-alone-in-two-studies-for-metastatic-non-small-cell-lung-cancer-nsclc/</loc>
		<lastmod>2025-03-08T04:39:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/seagen-astellas-and-merck-announce-results-of-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-and-padcev-as-monotherapy-in-first-line-advanced/</loc>
		<lastmod>2025-03-08T04:39:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-present-results-from-phase-3-leap-002-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocel/</loc>
		<lastmod>2025-03-08T04:39:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-foundation-launches-20-million-initiative-to-advance-equity-in-u-s-cancer-care/</loc>
		<lastmod>2025-03-08T04:39:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-in-combination-with-bevacizumab-and-as-monotherapy-demonstrates-clinically-meaningful-long-term-survival-in-certain-patients-with-first-line-advanced-ovarian-cancer-in-expl/</loc>
		<lastmod>2025-03-08T04:39:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-reports-strong-progress-in-esg-focus-areas/</loc>
		<lastmod>2025-03-08T04:39:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:39:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-japan-as-adjuvant-treatment-for-patients-with-brca-mutated-her2-negative-high-recurrent-risk-breast-cancer/</loc>
		<lastmod>2025-03-08T04:39:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-at-esmo-2022-congress-from-its-broad-oncology-portfolio-and-promising-pipeline-demonstrating-commitment-to-improving-long-term-survival-in-multiple-types-of-cancer/</loc>
		<lastmod>2025-03-08T04:39:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-submission-of-supplemental-new-drug-application-for-lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-metastatic-castration-resista/</loc>
		<lastmod>2025-03-08T04:39:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-fast-track-designation-from-the-u-s-fda-for-mk-2060-an-investigational-anticoagulant-therapy/</loc>
		<lastmod>2025-03-08T04:39:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-of-rna-technology/</loc>
		<lastmod>2025-03-08T04:39:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-002-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-versus-lenvima-monotherapy-in-patients-with-unresectable-hepatocellul/</loc>
		<lastmod>2025-03-08T04:39:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-approved-in-the-eu-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer/</loc>
		<lastmod>2025-03-08T04:39:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-921-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:39:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2022-dividend/</loc>
		<lastmod>2025-03-08T04:39:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2022-financial-results/</loc>
		<lastmod>2025-03-08T04:39:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-orion-announce-global-collaboration-for-the-development-and-commercialization-of-odm-208-an-investigational-steroid-synthesis-inhibitor-for-the-treatment-of-metastatic-castration-resistant/</loc>
		<lastmod>2025-03-08T04:39:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-412-trial-in-unresected-locally-advanced-head-and-neck-squamous-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:39:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2022-sales-and-earnings-conference-call-july-28/</loc>
		<lastmod>2025-03-08T04:39:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-the-launch-of-the-merck-digital-sciences-studio-to-help-healthcare-startups-quickly-bring-their-innovations-to-market/</loc>
		<lastmod>2025-03-08T04:39:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-adolescent-patients-%e2%89%a512-years-of-age-with-stage-iib-or-iic-melanoma-following-complete-resecti/</loc>
		<lastmod>2025-03-08T04:39:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-as-adjuvant-treatment-for-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer/</loc>
		<lastmod>2025-03-08T04:39:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/cdcs-acip-unanimously-votes-to-provisionally-recommend-use-of-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-as-an-option-for-pneumococcal-vaccination-in-infa/</loc>
		<lastmod>2025-03-08T04:39:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/results-from-phase-3-propel-trial-of-lynparza-olaparib-plus-abiraterone-in-first-line-metastatic-castration-resistant-prostate-cancer-published-in-nejm-evidence/</loc>
		<lastmod>2025-03-08T04:39:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/</loc>
		<lastmod>2025-03-08T04:39:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-positive-results-from-phase-1-2-study-evaluating-v116-the-companys-investigational-pneumococcal-conjugate-vaccine-for-adults/</loc>
		<lastmod>2025-03-08T04:39:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-that-chirfi-guindo-will-lead-marketing-for-merck-human-health/</loc>
		<lastmod>2025-03-08T04:39:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-2022-goldman-sachs-43rd-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:39:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-stage-ib-%e2%89%a54-centimeters-iiia-non-small-cell-lung-cancer-following-complete-surgical-resecti/</loc>
		<lastmod>2025-03-08T04:39:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-investor-event-to-highlight-oncology-portfolio-and-pipeline/</loc>
		<lastmod>2025-03-08T04:39:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-new-data-for-investigational-lagevrio-molnupiravir-from-phase-3-move-out-study/</loc>
		<lastmod>2025-03-08T04:39:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2022-dividend/</loc>
		<lastmod>2025-03-08T04:39:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/adjuvant-treatment-with-mercks-keytruda-pembrolizumab-demonstrates-statistically-significant-clinically-meaningful-improvement-in-distant-metastasis-free-survival-in-patients-with-r/</loc>
		<lastmod>2025-03-08T04:39:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-adolescent-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-c/</loc>
		<lastmod>2025-03-08T04:39:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple/</loc>
		<lastmod>2025-03-08T04:39:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-data-at-2022-asco-annual-meeting-highlighting-promising-pipeline-medicines-and-significant-progress-in-treating-earlier-stages-of-certain-cancers-with-keytruda-pembrolizumab/</loc>
		<lastmod>2025-03-08T04:39:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-deficient-mismatch-repair-dmmr-tumors-in-five-different-types/</loc>
		<lastmod>2025-03-08T04:39:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-bank-of-america-securities-2022-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:39:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2022-financial-results/</loc>
		<lastmod>2025-03-08T04:39:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose/</loc>
		<lastmod>2025-03-08T04:39:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-hig/</loc>
		<lastmod>2025-03-08T04:39:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ/</loc>
		<lastmod>2025-03-08T04:39:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-that-joseph-romanelli-will-lead-merck-human-health-international-effective-august-1-2022/</loc>
		<lastmod>2025-03-08T04:39:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need/</loc>
		<lastmod>2025-03-08T04:39:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2022-sales-and-earnings-conference-call-april-28/</loc>
		<lastmod>2025-03-08T04:39:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/</loc>
		<lastmod>2025-03-08T04:39:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/expansion-of-elkton-virginia-manufacturing-facility-to-further-increase-mercks-hpv-vaccine-supply-and-support-broader-and-equitable-access/</loc>
		<lastmod>2025-03-08T04:39:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-tumors-in-five-different-types/</loc>
		<lastmod>2025-03-08T04:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo/</loc>
		<lastmod>2025-03-08T04:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-retirement-of-dr-roy-d-baynes-dr-eliav-barr-appointed-head-of-global-clinical-development-and-chief-medical-officer/</loc>
		<lastmod>2025-03-08T04:40:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-c/</loc>
		<lastmod>2025-03-08T04:40:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-msi%e2%80%91h-dmmr-advanced-endometrial-carcinoma-who-have-disease-progression-following-prior-systemic-therapy-in-any-se/</loc>
		<lastmod>2025-03-08T04:40:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/systematic-review-and-meta-analysis-of-real-world-observational-studies-provide-additional-evidence-of-effectiveness-of-prevymis-in-preventing-cytomegalovirus-infection-and-disease-in-adults/</loc>
		<lastmod>2025-03-08T04:40:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-disease-free-survival-dfs-versus-placebo-as-adjuvant-therapy-in-patients-with-stage-ib-iiia-non-small-cell-lung-cancer-nsclc-r/</loc>
		<lastmod>2025-03-08T04:40:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keylynk-010-trial-evaluating-keytruda-pembrolizumab-in-combination-with-lynparza-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-to-stop-for-f/</loc>
		<lastmod>2025-03-08T04:40:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-reduced-risk-of-death-by-32-in-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer-in-phase-3-olympia-trial/</loc>
		<lastmod>2025-03-08T04:40:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-significant-improvement-in-distant-metastasis-free-survival-dmfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-resected-stage/</loc>
		<lastmod>2025-03-08T04:40:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-lynparza-olaparib-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-gbrcam-her2-negative-high-risk-early-breast-cancer-who-have-been-treated-with-neoadjuvant-or-adj/</loc>
		<lastmod>2025-03-08T04:40:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-cowens-42nd-annual-health-care-conference/</loc>
		<lastmod>2025-03-08T04:40:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-investor-event-to-highlight-growing-cardiovascular-portfolio-and-pipeline/</loc>
		<lastmod>2025-03-08T04:40:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-radically-unresectable-or-metastatic-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:40:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/dr-julie-l-gerberding-to-retire-from-merck/</loc>
		<lastmod>2025-03-08T04:40:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-new-leadership-for-human-health-business/</loc>
		<lastmod>2025-03-08T04:40:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-shares-environmental-social-governance-priorities-and-strategy/</loc>
		<lastmod>2025-03-08T04:40:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-event-to-discuss-long-term-environmental-social-governance-priorities/</loc>
		<lastmod>2025-03-08T04:40:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-plus-abiraterone-reduced-risk-of-disease-progression-or-death-by-34-versus-abiraterone-in-first-line-metastatic-castration-resistant-prostate-cancer-regardless-of-biomarker/</loc>
		<lastmod>2025-03-08T04:40:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/pivotal-phase-3-data-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc-published-in-the-new-england-journal-of-medicine/</loc>
		<lastmod>2025-03-08T04:40:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:40:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-that-3-1-million-courses-of-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-have-been-supplied-to-the-u-s-government-for-use-in-the-united-states/</loc>
		<lastmod>2025-03-08T04:40:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/</loc>
		<lastmod>2025-03-08T04:40:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-guggenheim-oncology-conference-2022/</loc>
		<lastmod>2025-03-08T04:40:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-demonstrated-activity-against-omicron-variant-in-in-vitro-studies/</loc>
		<lastmod>2025-03-08T04:40:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2022-dividend/</loc>
		<lastmod>2025-03-08T04:40:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery/</loc>
		<lastmod>2025-03-08T04:40:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/results-from-pivotal-phase-3-keynote-775-study-309-trial-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-advanced-endometrial-carcinoma-published-in-the-new-england-journal-of-med/</loc>
		<lastmod>2025-03-08T04:40:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-u-s-and-japan-regulatory-update-for-gefapixant/</loc>
		<lastmod>2025-03-08T04:40:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/frank-clyburn-to-leave-merck/</loc>
		<lastmod>2025-03-08T04:40:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-announce-supply-agreement-with-unicef-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine/</loc>
		<lastmod>2025-03-08T04:40:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-in-certain-patients-with-advanced-hepatocellular-carcinoma-hcc-previously-treated-with-sora/</loc>
		<lastmod>2025-03-08T04:40:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2021-sales-and-earnings-conference-call-on-february-3/</loc>
		<lastmod>2025-03-08T04:40:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-showed-statistically-significant-improvement-in-disease-free-survival-versus-placebo-as-adjuvant-treatment-for-patients-with-stage-ib-iiia-non-small-cell/</loc>
		<lastmod>2025-03-08T04:40:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:40:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer/</loc>
		<lastmod>2025-03-08T04:40:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-healthcare-c-suite-unscripted-conference/</loc>
		<lastmod>2025-03-08T04:40:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-u-s-regulatory-update-on-gefapixant/</loc>
		<lastmod>2025-03-08T04:40:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults/</loc>
		<lastmod>2025-03-08T04:40:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-expanded-indication-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-uroth/</loc>
		<lastmod>2025-03-08T04:40:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-new-first-line-indications-in-advanced-her2-negative-gastric-or-gej-adenocarcinoma-in-tumors-expressin/</loc>
		<lastmod>2025-03-08T04:40:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-continued-improvement-in-recurrence-free-survival-and-distant-metastasis-free-survival-in-pa/</loc>
		<lastmod>2025-03-08T04:40:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-rcc-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki/</loc>
		<lastmod>2025-03-08T04:40:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-ranks-no-1-on-newsweeks-list-of-americas-most-responsible-companies-2024/</loc>
		<lastmod>2025-03-08T04:40:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-receives-positive-cvmp-opinion-for-an-injectable-formulation-of-bravecto-fluralaner-for-use-in-dogs/</loc>
		<lastmod>2025-03-08T04:40:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-moderna-initiate-interpath-002-a-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-certain-types-of-resect/</loc>
		<lastmod>2025-03-08T04:40:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-001-trial-evaluating-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-patients-with-advanced-or-recurrent-endometrial-carcinom/</loc>
		<lastmod>2025-03-08T04:40:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keylynk-008-trial-evaluating-keytruda-pembrolizumab-plus-lynparza-olaparib-for-patients-with-metastatic-squamous-non-small-cell-lung-cancer-to-stop-for-futility/</loc>
		<lastmod>2025-03-08T04:40:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-patients-with-locally-advanced/</loc>
		<lastmod>2025-03-08T04:40:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small-cell-lung/</loc>
		<lastmod>2025-03-08T04:40:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2024-dividend/</loc>
		<lastmod>2025-03-08T04:40:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults-demonstrated-superior-immunogenicity-for-10-of-11-unique-serotypes-compared/</loc>
		<lastmod>2025-03-08T04:40:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-caraway-therapeutics-inc/</loc>
		<lastmod>2025-03-08T04:40:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction/</loc>
		<lastmod>2025-03-08T04:40:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference/</loc>
		<lastmod>2025-03-08T04:40:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-jefferies-london-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:40:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumabplus-gemcitabine-and-cisplatin-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer/</loc>
		<lastmod>2025-03-08T04:40:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-gemcitabine-and-cisplatin-as-treatment-for-patients-with-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer/</loc>
		<lastmod>2025-03-08T04:40:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-ubs-biopharma-conference/</loc>
		<lastmod>2025-03-08T04:40:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-significantly-improved-overall-survival-os-versus-placebo-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-nephrectomy/</loc>
		<lastmod>2025-03-08T04:40:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-death-by-more-than-half-versus-chemotherapy-in-patients-with-previously-untreated-locally-advanced-or-metasta/</loc>
		<lastmod>2025-03-08T04:40:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2023-financial-results/</loc>
		<lastmod>2025-03-08T04:40:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-welireg-belzutifan-significantly-improved-progression-free-survival-and-objective-response-rates-versus-everolimus-in-certain-previously-treated-patients-with-advanced-renal-ce/</loc>
		<lastmod>2025-03-08T04:40:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-significantly-improved-progression-free-survival-pfs-versus-concurrent-chemoradiotherapy-alone-in-newly-diagnosed-hi/</loc>
		<lastmod>2025-03-08T04:40:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significant-improvement-in-pathological-complete-response-pcr-rate-as-neoadjuvant-therapy-versus-chemotherapy-in/</loc>
		<lastmod>2025-03-08T04:40:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-single-agent-after-surgery-reduced-risk-of-death-by-28-versus-pre-operative-chemotherapy-in-resectable-stage-ii-iiia-o/</loc>
		<lastmod>2025-03-08T04:40:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-significantly-improved-progression-free-survival-pfs-versus-trastuzumab-and-chemotherapy-in-first-line-her2-positive-advanced-gastric/</loc>
		<lastmod>2025-03-08T04:40:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-prevymis-for-prevention-of-cmv-disease-in-high-risk-adult-kidney-transplant-recipients-and-extended-200-day-dosing-in-adult-hsct-recipients-at-risk-fo/</loc>
		<lastmod>2025-03-08T04:40:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/</loc>
		<lastmod>2025-03-08T04:40:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based/</loc>
		<lastmod>2025-03-08T04:40:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-resectable-t%e2%89%a54-cm-or-n-nsclc-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-a-single/</loc>
		<lastmod>2025-03-08T04:40:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-her2-negative-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinom/</loc>
		<lastmod>2025-03-08T04:40:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-pivotal-keynote-671-trial-meets-dual-primary-endpoint-of-overall-survival-os-in-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer-nsclc/</loc>
		<lastmod>2025-03-08T04:40:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-highlights-innovative-oncology-portfolio-and-pipeline-at-esmo-congress-2023-underscoring-commitment-to-advancing-cancer-research-and-improving-patient-outcomes-across-multiple-stages-of-disease/</loc>
		<lastmod>2025-03-08T04:40:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-third-quarter-2023-sales-and-earnings-conference-call-oct-26/</loc>
		<lastmod>2025-03-08T04:40:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-met-primary-endpoint-of-disease-free-survival-dfs-in-certain-patients-with-muscle-invasive-urothelial-carcinoma-miuc-after-surgery/</loc>
		<lastmod>2025-03-08T04:40:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah/</loc>
		<lastmod>2025-03-08T04:40:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-a39-ev-302-trial-met-dual-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-certain-patients-with-previously-untreated-locally-advanced/</loc>
		<lastmod>2025-03-08T04:40:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-two-phase-3-trials-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-metastatic-non-small-cell-lung-cancer/</loc>
		<lastmod>2025-03-08T04:40:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-for-priority-review-mercks-supplemental-new-drug-application-for-welireg-belzutifan-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma-rcc/</loc>
		<lastmod>2025-03-08T04:40:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-as-treatment-for-patients-with-newly-diagnosed-high-risk-locally-advanced/</loc>
		<lastmod>2025-03-08T04:40:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and/</loc>
		<lastmod>2025-03-08T04:40:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-expands-mercks-ervebo-ebola-zaire-vaccine-rvsv%ce%b4g-zebov-gp-live-indication-to-include-children-1-year-of-age-and-older/</loc>
		<lastmod>2025-03-08T04:40:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-presents-new-analyses-supporting-the-promising-potential-of-sotatercept-its-investigational-medicine-for-adults-with-pulmonary-arterial-hypertension-pah/</loc>
		<lastmod>2025-03-08T04:40:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:40:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/long-term-follow-up-data-on-sustained-immunogenicity-and-safety-for-gardasil9-published-in-pediatrics/</loc>
		<lastmod>2025-03-08T04:40:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-citi-18th-annual-biopharma-conference/</loc>
		<lastmod>2025-03-08T04:40:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcino/</loc>
		<lastmod>2025-03-08T04:40:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-010-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-recurrent-or-metastatic-head-and-ne/</loc>
		<lastmod>2025-03-08T04:40:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-initiates-phase-3-clinical-program-for-oral-pcsk9-inhibitor-candidate-mk-0616/</loc>
		<lastmod>2025-03-08T04:40:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-welireg-belzutifan-phase-3-litespark-005-trial-met-primary-endpoint-of-progression-free-survival-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:40:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparibplus-abiraterone-and-prednisone-or-prednisolone-approved-in-japan-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:40:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/</loc>
		<lastmod>2025-03-08T04:40:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-756-trial-met-primary-endpoint-of-pathological-complete-response-pcr-rate-in-patients-with-high-risk-early-stage-er-her2-breast-cancer/</loc>
		<lastmod>2025-03-08T04:40:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2023-financial-results/</loc>
		<lastmod>2025-03-08T04:40:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-moderna-initiate-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-high-riskstage-iib-iv-melanom/</loc>
		<lastmod>2025-03-08T04:40:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-met-key-immunogenicity-and-safety-endpoints-in-two-phase-3-trials/</loc>
		<lastmod>2025-03-08T04:40:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2023-dividend/</loc>
		<lastmod>2025-03-08T04:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastroesophageal-junction-ge/</loc>
		<lastmod>2025-03-08T04:41:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-european-union-chmp-opinion-for-gefapixant/</loc>
		<lastmod>2025-03-08T04:41:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2023-sales-and-earnings-conference-call-on-aug-1/</loc>
		<lastmod>2025-03-08T04:41:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-a18-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/</loc>
		<lastmod>2025-03-08T04:41:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/</loc>
		<lastmod>2025-03-08T04:41:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-585-trial-in-locally-advanced-resectable-gastric-and-gastroesophageal-junction-gej-adenocarcinoma/</loc>
		<lastmod>2025-03-08T04:41:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-district-court-for-the-district-of-new-jersey-rules-in-favor-of-merck-in-patent-infringement-lawsuit-related-to-bridion-sugammadex/</loc>
		<lastmod>2025-03-08T04:41:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-met-primary-endpoint-of-progression-free-survival-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesop/</loc>
		<lastmod>2025-03-08T04:41:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-advanced-or-unresectable-biliary-tract-cancer/</loc>
		<lastmod>2025-03-08T04:41:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-data-for-efinopegdutide-mk-6024-an-investigational-glp-1-glucagon-receptor-co-agonist-in-patients-with-nonalcoholic-fatty-liver-disease-nafld-at-easl-2023/</loc>
		<lastmod>2025-03-08T04:41:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-approves-new-indication-for-mercks-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-disease-in-high-risk-adult-kidney-transplant-recipients/</loc>
		<lastmod>2025-03-08T04:41:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free/</loc>
		<lastmod>2025-03-08T04:41:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:41:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-unresectable-advanced-pleural-mesothelioma/</loc>
		<lastmod>2025-03-08T04:41:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-reduced-the-risk-of-event-free-survival-events-by-42-versus-pre-operative/</loc>
		<lastmod>2025-03-08T04:41:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-lynparza-olaparibplus-abiraterone-and-prednisone-or-prednisolone-for-treatment-of-adult-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/</loc>
		<lastmod>2025-03-08T04:41:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2023-dividend/</loc>
		<lastmod>2025-03-08T04:41:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrates-long-term-durable-survival-benefit-versus-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma/</loc>
		<lastmod>2025-03-08T04:41:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-bank-of-america-securities-2023-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:41:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-extensive-new-research-demonstrating-significant-progress-in-the-treatment-of-certain-earlier-stage-cancers-and-in-advancing-broad-oncology-pipeline-at-2023-asco-annual-meeting/</loc>
		<lastmod>2025-03-08T04:41:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/update-on-fda-advisory-committee-vote-on-lynparza-olaparib-plus-abiraterone-and-prednisone-or-prednisolone-in-first-line-metastatic-castration-resistant-prostate-cancer/</loc>
		<lastmod>2025-03-08T04:41:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in/</loc>
		<lastmod>2025-03-08T04:41:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2023-financial-results/</loc>
		<lastmod>2025-03-08T04:41:13+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/</loc>
		<lastmod>2025-03-08T04:41:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-compared-to-chemotherapy-alone-in-patients-with-advanced-or-unresectable-biliary-tract-cancer/</loc>
		<lastmod>2025-03-08T04:41:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junctio/</loc>
		<lastmod>2025-03-08T04:41:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-receives-prime-scheme-designation-from-the-european-medicines-agency-for-adjuva/</loc>
		<lastmod>2025-03-08T04:41:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-trials-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-certain-patients-with-advanced-melanoma-leap-003-and-metastatic-colorectal-cance/</loc>
		<lastmod>2025-03-08T04:41:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2023-sales-and-earnings-conference-call-on-april-27/</loc>
		<lastmod>2025-03-08T04:41:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic/</loc>
		<lastmod>2025-03-08T04:41:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:41:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient/</loc>
		<lastmod>2025-03-08T04:41:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-from-open-label-arm-of-phase-2-keyvibe-002-trial-evaluating-mk-7684a-a-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small/</loc>
		<lastmod>2025-03-08T04:41:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-barclays-2023-global-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:41:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-malignant-pleural-mesothelioma/</loc>
		<lastmod>2025-03-08T04:41:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/</loc>
		<lastmod>2025-03-08T04:41:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-investigational-activin-signaling-inhibitor-sotatercept-improved-six-minute-walk-distance-by-40-8-meters-at-week-24-versus-placebo-in-adults-with-pulmonary-arterial-hypertension-on-bac/</loc>
		<lastmod>2025-03-08T04:41:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-astrazeneca-provide-update-on-us-regulatory-review-of-lynparza-olaparib-for-use-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-the-treatment-of-metastatic-castrat/</loc>
		<lastmod>2025-03-08T04:41:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/us-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines-m-m-rii-measles-mumps-and-rubella-virus-vaccine-live-varivax-varicella-virus-vaccine-live-and-proquad/</loc>
		<lastmod>2025-03-08T04:41:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-trials-keynote-641-and-keynote-789/</loc>
		<lastmod>2025-03-08T04:41:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-671-trial-met-primary-endpoint-of-event-free-survival-efs-in-patients-with-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer/</loc>
		<lastmod>2025-03-08T04:41:23+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-provide-update-on-eu-marketing-authorization-application-for-lagevrio-molnupiravir/</loc>
		<lastmod>2025-03-08T04:41:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-opens-enrollment-in-new-phase-3-clinical-trials-with-investigational-once-daily-islatravir-in-combination-with-doravirine-for-treatment-of-hiv-1-infection/</loc>
		<lastmod>2025-03-08T04:41:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-was-granted-breakthrough-therapy-designation-by-the/</loc>
		<lastmod>2025-03-08T04:41:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/</loc>
		<lastmod>2025-03-08T04:41:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-for-sotatercept-and-mk-0616-at-acc-23-wcc-demonstrating-significant-progress-in-advancing-its-innovative-cardiovascular-pipeline/</loc>
		<lastmod>2025-03-08T04:41:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction/</loc>
		<lastmod>2025-03-08T04:41:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-supplemental-new-drug-application-for-mercks-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-kidney-transplant-recipients-at-high-risk/</loc>
		<lastmod>2025-03-08T04:41:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-astrazeneca-present-final-results-of-key-secondary-overall-survival-endpoint-from-phase-3-propel-trial-at-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium/</loc>
		<lastmod>2025-03-08T04:41:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma/</loc>
		<lastmod>2025-03-08T04:41:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-as-adjuvant-treatment-following-surgical-resection-and-platinum-based-chemotherapy-for-patients-with-stage-ib-t2a-%e2%89%a54-centimeters-ii-or-iiia-non/</loc>
		<lastmod>2025-03-08T04:41:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/</loc>
		<lastmod>2025-03-08T04:41:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-keynote-991-trial-evaluating-keytruda-pembrolizumab-plus-enzalutamide-and-androgen-deprivation-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-stop-for/</loc>
		<lastmod>2025-03-08T04:41:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2023-dividend/</loc>
		<lastmod>2025-03-08T04:41:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-in-first-line-advanced-or-unresectable-biliary-tract-cancer-in-keynote-966/</loc>
		<lastmod>2025-03-08T04:41:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-named-one-of-americas-most-just-companies-by-just-capital-and-cnbc-industry-leader-in-pharmaceuticals-and-biotech/</loc>
		<lastmod>2025-03-08T04:41:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-tender-offer-to-acquire-imago-biosciences-inc/</loc>
		<lastmod>2025-03-08T04:41:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-08T04:41:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2022-sales-and-earnings-conference-call-february-2/</loc>
		<lastmod>2025-03-08T04:41:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-10T04:04:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-gardasil-receives-expanded-approval-for-males-in-china/</loc>
		<lastmod>2025-03-10T04:04:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2024-sales-and-earnings-conference-call-feb-4/</loc>
		<lastmod>2025-03-10T04:04:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-015-trial-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-combination-with-chemotherapy-in-patients-with-certain-types-of-ga/</loc>
		<lastmod>2025-03-10T22:21:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-pheochromocytoma-and-paraganglioma-ppgl/</loc>
		<lastmod>2025-03-12T14:42:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-data-from-phase-3-trials-that-show-the-investigational-once-daily-oral-two-drug-regimen-of-doravirine-islatravir-dor-isl-maintained-hiv-1-viral-suppression-at-week-48/</loc>
		<lastmod>2025-03-12T15:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-unveils-new-facility-to-increase-vaccine-production-capacity/</loc>
		<lastmod>2025-03-12T15:38:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications/</loc>
		<lastmod>2025-03-12T15:38:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-td-cowen-45th-annual-health-care-conference/</loc>
		<lastmod>2025-03-12T15:38:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-standard-of-care-as-perioperative-treatment-for-resectable-locally-advanced-head-and-neck-squamous-cel/</loc>
		<lastmod>2025-03-12T15:38:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-waveline-010-trial-initiation-evaluating-zilovertamab-vedotin-an-investigational-antibody-drug-conjugate-for-the-treatment-of-patients-with-previously-untreated-diffuse-large/</loc>
		<lastmod>2025-03-12T15:38:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/</loc>
		<lastmod>2025-03-12T15:38:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-decision-to-stop-phase-3-hyperion-trial-evaluating-winrevair-sotatercept-csrk-early-and-move-to-final-analysis/</loc>
		<lastmod>2025-03-12T15:38:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-pneumococcal-vaccination-in-adults/</loc>
		<lastmod>2025-03-12T15:38:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2025-dividend-and-10-billion-share-repurchase-authorization/</loc>
		<lastmod>2025-03-12T15:38:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-closes-exclusive-global-license-agreement-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody/</loc>
		<lastmod>2025-03-12T15:52:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-for-the-treatment-of-adults/</loc>
		<lastmod>2025-03-12T15:52:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-glp-1-receptor-agonist/</loc>
		<lastmod>2025-03-12T15:52:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fda-acceptance-of-biologics-license-application-for-clesrovimab-an-investigational-long-acting-monoclonal-antibody-designed-to-protect-infants-from-rsv-disease-during-their-first-rsv/</loc>
		<lastmod>2025-03-12T15:52:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs-evaluating-investigational-vibostolimab-and-favezelimab-fixed-dose-combinations-with-pembrolizumab/</loc>
		<lastmod>2025-03-12T15:52:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-china-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-after-surgery-as-adjuvant-treatment-for-patien/</loc>
		<lastmod>2025-03-12T15:52:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-welireg-belzutifan-as-treatment-for-adult-patients-with-certain-types-of-von-hippel-lindau-disease-associated-tumors-and-for-certain-previously-trea/</loc>
		<lastmod>2025-03-12T15:52:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/lynparza-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-3-trial/</loc>
		<lastmod>2025-03-12T15:52:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-advanced-epithelial-ovarian-cancer/</loc>
		<lastmod>2025-03-12T15:52:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in-phase-2-trial-of-previously-untreated-patients-with-diff/</loc>
		<lastmod>2025-03-12T15:52:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-phase-3-study-move-now-evaluating-lagevrio-molnupiravir-for-the-treatment-of-covid-19-in-high-risk-adults/</loc>
		<lastmod>2025-03-12T15:52:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-sac-tmt-for-the-treatment-of-certain-patients-with-previously-treated-advanced-or-metastatic-nonsquamous-non-small-cell-lung-ca/</loc>
		<lastmod>2025-03-12T15:52:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-citi-2024-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:52:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevair-sotatercept-csrk-met-primary-endpoint-at-interim-analysis/</loc>
		<lastmod>2025-03-12T15:52:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-recommends-rejection-of-trc-capitals-mini-tender-offer-2/</loc>
		<lastmod>2025-03-12T15:52:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference/</loc>
		<lastmod>2025-03-12T15:52:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-welireg-belzutifan-approved-in-china-for-the-treatment-of-adult-patients-with-certain-types-of-von-hippel-lindau-vhl-disease-associated-tumors/</loc>
		<lastmod>2025-03-12T15:52:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/surendralal-karsanbhai-elected-to-merck-board-of-directors/</loc>
		<lastmod>2025-03-12T15:52:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-data-at-the-ash-2024-annual-meeting-highlights-promising-hematology-pipeline-with-diverse-range-of-investigational-assets-and-novel-modalities/</loc>
		<lastmod>2025-03-12T15:52:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2025-dividend/</loc>
		<lastmod>2025-03-12T15:52:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints/</loc>
		<lastmod>2025-03-12T15:52:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-non-epithelioid-malignant-pleural-mesothelioma/</loc>
		<lastmod>2025-03-12T15:52:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-jefferies-london-healthcare-conference-2/</loc>
		<lastmod>2025-03-12T15:52:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/</loc>
		<lastmod>2025-03-12T15:53:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/koselugo-selumetinib-showed-significant-and-clinically-meaningful-improvement-in-objective-response-rate-versus-placebo-in-adults-with-neurofibromatosis-type-1-who-have-symptomatic-inoperable/</loc>
		<lastmod>2025-03-12T15:53:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-from-gardasil9-studies-reinforcing-the-importance-of-gender-neutral-hpv-vaccination-in-adults-up-to-age-45-at-the-international-papillomavirus-conference-ipvc-2024/</loc>
		<lastmod>2025-03-12T15:53:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-ubs-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:53:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2024-financial-results/</loc>
		<lastmod>2025-03-12T15:53:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-ty/</loc>
		<lastmod>2025-03-12T15:53:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-30th-approval-from-european-commission-with-two-new-indications-in-gynecologic-cancers/</loc>
		<lastmod>2025-03-12T15:53:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/cdcs-acip-recommends-mercks-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-pneumococcal-vaccination-in-adults-50-years-of-age-and-older/</loc>
		<lastmod>2025-03-12T15:53:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/gilead-and-merck-announce-phase-2-data-showing-a-treatment-switch-to-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-in-adults-at-wee/</loc>
		<lastmod>2025-03-12T15:53:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv-preventative-monoclonal-antibody-significantly-reduced-incidence-of-rsv-disease-and-hospitalization-in-heal/</loc>
		<lastmod>2025-03-12T15:53:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-capvaxive-pneumococcal-21-valent-conjugate-vaccine-demonstrates-positive-immune-responses-in-adults-with-increased-risk-for-pneumococcal-disease/</loc>
		<lastmod>2025-03-12T15:53:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/exelixis-and-merck-sign-clinical-development-collaboration-to-evaluate-investigational-zanzalintinib-in-combination-with-keytruda-pembrolizumab-in-head-and-neck-cancer-and-in-combination-with/</loc>
		<lastmod>2025-03-12T15:53:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/new-data-to-be-presented-at-idweek-2024-reinforce-mercks-broad-and-diverse-vaccines-and-infectious-disease-pipeline-and-portfolio/</loc>
		<lastmod>2025-03-12T15:53:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-met-primary-endpoint-of-event-free-survival-efs-as-perioperative-treatment-regimen-in-patients-with-resected-locally-advanced-head-and-neck-squamous-c/</loc>
		<lastmod>2025-03-12T15:53:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-investigational-b-cell-depletion-therapy-cn201-from-curon-biopharmaceutical/</loc>
		<lastmod>2025-03-12T15:53:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-third-quarter-2024-sales-and-earnings-conference-call-oct-31/</loc>
		<lastmod>2025-03-12T15:53:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-long-term-data-for-tulisokibart-mk-7240-an-investigational-anti-tl1a-monoclonal-antibody-in-inflammatory-bowel-disease-at-ueg-week-2024/</loc>
		<lastmod>2025-03-12T15:53:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed-dose-combination-of-favezelimab-and-pembrolizumab-for-patients-with-previously-treated-pd-l1-positive-microsatellite/</loc>
		<lastmod>2025-03-12T15:53:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-new-approvals-in-japan-for-certain-patients-with-non-small-cell-lung-carcinoma-nsclc-and-radically-unresectable-urothelial-carcinoma/</loc>
		<lastmod>2025-03-12T15:53:33+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-regimens-as-treatment-for-patients-with-two-types-of-gynecologic-cancers/</loc>
		<lastmod>2025-03-12T15:53:35+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-advanced-or-metastatic-malignant-pleu/</loc>
		<lastmod>2025-03-12T15:53:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression-free-survival-versus-doublet-chemotherapy-in-patients-with-locally-advanced-or-metastatic-egfr-mutated-non-small/</loc>
		<lastmod>2025-03-12T15:53:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-single-agent-after-surgery-reduced-risk-of-death-by-more-than-one-third-34-versus-neoadjuvant-chemotherapy-in-high-ri/</loc>
		<lastmod>2025-03-12T15:53:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ten-year-data-for-mercks-keytruda-pembrolizumab-demonstrates-sustained-overall-survival-benefit-versus-ipilimumab-in-advanced-melanoma/</loc>
		<lastmod>2025-03-12T15:53:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-combination-with-transarterial-chemoembolization-significantly-improved-progression-free-survival-compared-to-tace-alone-in-patients-w/</loc>
		<lastmod>2025-03-12T15:53:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of-death-by-33-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/</loc>
		<lastmod>2025-03-12T15:53:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-significantly-improved-overall-survival-os-versus-trastuzumab-and-chemotherapy-alone-in-first-line-treatment-of-patients-with-her2-po/</loc>
		<lastmod>2025-03-12T15:53:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-bank-of-america-2024-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:53:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and-safety-of-gardasil9-in-japanese-males/</loc>
		<lastmod>2025-03-12T15:53:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in-patients-with-extensive-stage-small-cell-lung-cancer-in-ideate-lung01-phase-2-trial/</loc>
		<lastmod>2025-03-12T15:53:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-survival-data-and-new-research-on-10-investigational-or-approved-medicines-at-esmo-congress-2024/</loc>
		<lastmod>2025-03-12T15:53:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-eyebio-announce-initiation-of-phase-2b-3-clinical-trial-for-restoret-for-the-treatment-of-diabetic-macular-edema/</loc>
		<lastmod>2025-03-12T15:53:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma-in-ad/</loc>
		<lastmod>2025-03-12T15:53:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:53:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials/</loc>
		<lastmod>2025-03-12T15:54:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for-the-treatment-of-certain-patients-with-essential-thrombocythemia/</loc>
		<lastmod>2025-03-12T15:54:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-european-commission-approval-for-winrevair-sotatercept-in-combination-with-other-pulmonary-arterial-hypertension-pah-therapies-for-the-treatment-of-pah-in-adult-patients-w/</loc>
		<lastmod>2025-03-12T15:54:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-investigational-b-cell-depletion-therapy-cn201-from-curon-biopharmaceutical/</loc>
		<lastmod>2025-03-12T15:54:06+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keyvibe-008-trial-evaluating-an-investigational-fixed-dose-combination-of-vibostolimab-and-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer/</loc>
		<lastmod>2025-03-12T15:54:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/</loc>
		<lastmod>2025-03-12T15:54:10+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/ideate-lung02-phase-3-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer/</loc>
		<lastmod>2025-03-12T15:54:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2024-financial-results/</loc>
		<lastmod>2025-03-12T15:54:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-line-treatment-for-patients-with-unresectable-or-metastatic-urothelial-c/</loc>
		<lastmod>2025-03-12T15:54:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-2024-dividend/</loc>
		<lastmod>2025-03-12T15:54:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-topline-results-from-phase-2b-3-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants/</loc>
		<lastmod>2025-03-12T15:54:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-share-new-research-and-host-community-focused-symposia-at-aids-2024/</loc>
		<lastmod>2025-03-12T15:54:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-eyebio/</loc>
		<lastmod>2025-03-12T15:54:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-completes-acquisition-of-elancos-aqua-business/</loc>
		<lastmod>2025-03-12T15:54:28+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-and-orion-announce-mutual-exercise-of-option-providing-merck-global-exclusive-rights-to-opevesostat-an-investigational-cyp11a1-inhibitor-for-the-treatment-of-metastatic-castration-resistant-pr/</loc>
		<lastmod>2025-03-12T15:54:30+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-second-quarter-2024-sales-and-earnings-conference-call-july-30/</loc>
		<lastmod>2025-03-12T15:54:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-winrevair-sotatercept-in-pulmonary-arterial-hypertension-pah/</loc>
		<lastmod>2025-03-12T15:54:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/</loc>
		<lastmod>2025-03-12T15:54:36+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/usda-approves-merck-animal-healths-nobivac-nxt-canine-flu-h3n2-the-first-and-only-rna-particle-technology-vaccine-for-canine-influenza/</loc>
		<lastmod>2025-03-12T15:54:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/u-s-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/</loc>
		<lastmod>2025-03-12T15:54:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-carboplatin-and-paclitaxel-as-treatment-for-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma/</loc>
		<lastmod>2025-03-12T15:54:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:54:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su/</loc>
		<lastmod>2025-03-12T15:54:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-of-patients-with-unresectable-advanced-or-metastatic-malignant-pl/</loc>
		<lastmod>2025-03-12T15:54:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-eyebio/</loc>
		<lastmod>2025-03-12T15:54:46+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-third-quarter-2024-dividend/</loc>
		<lastmod>2025-03-12T15:54:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-its-overall-survival-os-endpoint-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc/</loc>
		<lastmod>2025-03-12T15:54:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-present-new-data-at-2024-asco-annual-meeting-demonstrating-advancements-in-novel-oncology-treatment-approaches-across-broad-portfolio-and-diverse-pipeline/</loc>
		<lastmod>2025-03-12T15:54:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keyvibe-010-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-as-adjuvant-treatment-for-patients-with-resected-high-risk-melanoma/</loc>
		<lastmod>2025-03-12T15:54:53+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-b21-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-radiotherapy-for-patients-with-newly-diagnosed-high-risk-endometrial-c/</loc>
		<lastmod>2025-03-12T15:54:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-expands-access-to-high-quality-maternal-care-for-more-than-30-million-women-worldwide-through-merck-for-mothers/</loc>
		<lastmod>2025-03-12T15:54:56+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-bank-of-america-securities-2024-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:54:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej/</loc>
		<lastmod>2025-03-12T15:54:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-data-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults/</loc>
		<lastmod>2025-03-12T15:55:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-first-quarter-2024-financial-results/</loc>
		<lastmod>2025-03-12T15:55:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-initiates-phase-3-clinical-trial-of-mk-1084-an-investigational-oral-kras-g12c-inhibitor-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-certain-patients-with-met/</loc>
		<lastmod>2025-03-12T15:55:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/rejoice-ovarian01-phase-2-3-trial-of-raludotatug-deruxtecan-initiated-in-patients-with-platinum-resistant-ovarian-cancer/</loc>
		<lastmod>2025-03-12T15:55:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-first-quarter-2024-sales-and-earnings-conference-call-april-25/</loc>
		<lastmod>2025-03-12T15:55:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-resectable-non-small-ce/</loc>
		<lastmod>2025-03-12T15:55:09+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1/</loc>
		<lastmod>2025-03-12T15:55:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-provides-update-on-phase-3-keylynk-006-trial-evaluating-keytruda-pembrolizumab-plus-maintenance-lynparza-olaparib-for-certain-patients-with-metastatic-nonsquamous-non-small-cell/</loc>
		<lastmod>2025-03-12T15:55:12+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-positive-data-on-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-demonstrated-immune-responses-in-adults/</loc>
		<lastmod>2025-03-12T15:55:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-significantly-improved-overall-survival-os-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-ce/</loc>
		<lastmod>2025-03-12T15:55:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-plans-to-conduct-clinical-trials-of-a-novel-investigational-multi-valent-human-papillomavirus-hpv-vaccine-and-single-dose-regimen-for-gardasil-9/</loc>
		<lastmod>2025-03-12T15:55:18+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/</loc>
		<lastmod>2025-03-12T15:55:19+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/gilead-and-merck-announce-phase-2-data-showing-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-at-week-24/</loc>
		<lastmod>2025-03-12T15:55:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-barclays-26th-annual-global-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:55:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-leerink-partners-global-biopharma-conference-2024/</loc>
		<lastmod>2025-03-12T15:55:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-td-cowen-44th-annual-health-care-conference/</loc>
		<lastmod>2025-03-12T15:55:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-the-treat/</loc>
		<lastmod>2025-03-12T15:55:27+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-primary-advanced-or-recurrent-endometrial-carcinoma/</loc>
		<lastmod>2025-03-12T15:55:29+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business-2/</loc>
		<lastmod>2025-03-12T15:55:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/</loc>
		<lastmod>2025-03-12T15:55:37+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-death-by-38-versus-placebo-as-adjuvant-therapy-for-patients-with-renal-cell-carcinoma-rcc-at-an-increased-risk-of-recurrence-follow/</loc>
		<lastmod>2025-03-12T15:55:39+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/mercks-keytruda-pembrolizumab-significantly-improved-disease-free-survival-dfs-as-adjuvant-therapy-versus-observation-in-high-risk-patients-with-localized-muscle-invasive-and-locall/</loc>
		<lastmod>2025-03-12T15:55:41+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-second-quarter-2024-dividend/</loc>
		<lastmod>2025-03-12T15:55:42+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-hold-fourth-quarter-and-full-year-2023-sales-and-earnings-conference-call-feb-1/</loc>
		<lastmod>2025-03-12T15:55:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-plus-chemoradiotherapy-as-treatment-for-patients-with-figo-2014-stage-iii-iva-cervical-cancer/</loc>
		<lastmod>2025-03-12T15:55:45+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/</loc>
		<lastmod>2025-03-12T15:55:47+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-announces-phase-3-trial-initiations-for-four-investigational-candidates-from-its-promising-hematology-and-oncology-pipeline/</loc>
		<lastmod>2025-03-12T15:55:48+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.merck.com/news/merck-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2025-03-12T15:55:50+00:00</lastmod>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->